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 ABSTRACT 
Lin Xiao: Regulation of Endothelial Plasticity by TGFβ in Tumors 
(Under the direction of Andrew Dudley) 
 
Tumor endothelial cells (TEC) are abnormal in morphology, structure, and function. They 
exhibit high cellular plasticity and may acquire stem-cell features in response to the aberrant 
tumor microenvironment. Such ability of TEC is prominently manifested in a process termed 
endothelial-mesenchymal transition, or EndMT. During EndMT, TEC lose their endothelial 
characteristics and gain fibroblast gene expression, transdifferentiating into mesenchymal cells 
in response to inflammatory factors, especially the chief inducer of EndMT, transforming growth 
factor beta (TGFβ). Although EndMT has been described as a physiological process in cardiac 
development during embryogenesis, in tumors EndMT may contribute to vascular abnormalities, 
generate tumor-promoting myofibroblasts, and lead to development of resistance to anti-cancer 
therapies that target the tumor vasculature. This thesis aims to understand the mechanisms that 
un derlie EndMT and identify regulatory factors that counteract this process in tumors. 
During the project, we developed an efficient TEC isolation method that allowed us to 
obtain highly pure TEC populations free of contaminating tumor or mesenchymal cells. We 
found that the TEC isolated from mammary tumors possessed a unique gene signature that was 
retained in culture. We also uncovered two distinct TEC populations that responded differently 
to TGFβ: some TEC transdifferentiated into myofibroblast-like cells, whereas others were more 
resistant to TGFβ challenge. In addition, basic fibroblast growth factor (bFGF), which is an 
important endothelial mitogen, preserved endothelial identity by opposing TGFβ-induced 
EndMT. 
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Interestingly, TEC were found to possess an intrinsic protective mechanism whereby bFGF was 
up-regulated and secreted to neutralize the effect of TGFβ during EndMT. Further elucidation of 
the molecular pathways that regulate TEC heterogeneity and plasticity may facilitate the 
development of specific drugs to target myofibroblasts and to reverse myofibroblast 
differentiation in tumors and other fibrotic diseases.  
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CHAPTER 1: Endothelial-Mesenchymal Transition and Its Regulators in Tumors 
Overview 
Endothelial cells (EC) form the innermost layer of the vascular system, lining the entire 
blood and lymphatic vessels. This monolayer of cells, measuring an average of less than one 
micron in thickness, is not merely part of passive conduits for nutrient and oxygen transport, but 
is highly plastic and metabolically active. Studies of past decades have established that the 
endothelium is integral to many physiological and pathological processes in virtually all tissues 
of the body. In tumors, an aberrant microenvironment promotes dysregulated angiogenesis and 
endothelial dysfunction. Tumor-specific EC (TEC) can acquire stem-cell futures and undergo 
endothelial-mesenchymal transition (EndMT), where EC transdifferentiate into mesenchymal 
cells, a process triggered mainly by a cytokine called transforming growth factor beta (TGFβ).  
In the following chapter, a description of endothelial heterogeneity and plasticity of both 
normal and tumor endothelium will be presented, along with summaries of studies on 
developmental and pathological EndMT. Literature review of the regulatory factors of EndMT 
will emphasize largely the pathways regulated by two opposing mediators of EndMT, namely, 
TGFβ and bFGF, which are the main focus of this thesis. The final section of this introduction 
will discuss the implications of EndMT in tumors and other diseases, and will also include a 
number of unanswered questions in the field for future studies. 
Endothelial heterogeneity and plasticity 
EC originate from a group of progenitor cells called angioblasts. Although how precisely 
these progenitor cells are specified is still controversial, angioblasts are shown to be 
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heterogeneous in their lineages. Studies of both avian species and mice have revealed that 
some angioblasts and hematopoietic stem cells share the same common predecessors called 
hemangioblasts, whereas other angioblasts derive independently from progressive restriction of 
mesoderm in response to a series of growth signals, including Notch, vascular endothelial 
growth factor (VEGF), and bone morphogenetic proteins (BMPs) 1,2. Angioblasts then develop 
into the blood vascular system through two distinct processes: vasculogenesis where 
angioblasts differentiate and assemble into a primitive vascular plexus of capillaries along with 
some vessels such as presumptive dorsal aortae and cardinal veins, and angiogenesis where 
new vessels are formed from the preexisting vasculature 1,3. Both processes can occur 
concurrently once an initial vascular plexus is established, and the vascular network undergoes 
extensive remodeling to establish a patent, functional system. Another parallel system, the 
lymphatic vasculature, arises from the venous EC of the anterior cardinal vein. A subset of 
these venous EC morph into lymphatic EC, which first form lymphatic sacs and then bud off the 
cardinal vein, eventually ramifying into a separate network that returns the excessive 
extravasated fluid to the blood circulation 4. Mature lymphatic EC are identified by a number of 
molecular markers, including LYVE-1, PROX-1, and podoplanin, which are not observed in the 
blood EC (Table 1-1). However, many of these markers are also expressed in other cell types 
that are often derived from the same lineages (Table 1-1).  
Although the endothelium is a single monolayer of cells that maintains the integrity of the 
vasculature, endothelial heterogeneity is manifested from the early embryonic stage where 
arterial and venous specification in the capillary plexus is determined by both intrinsic (e.g., 
epigenetic) and extrinsic (e.g., hemodynamic forces) factors 3,5. As the vascular network 
integrates into the growing organs, EC specialize into subpopulations to meet the demands of 
the local tissues, and start to display phenotypical, functional, and gene expression differences 
6.  
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The intracellular structural heterogeneity of EC was first revealed by electron microscopy 
in the 1960s, an observation that suggests functional diversity of the endothelium 7. Distinct 
endothelial morphologies were also observed in different vascular beds. For example, the brain 
endothelium consists of tightly connected EC surrounded by a continuous basement membrane 
(continuous endothelium), glomerulus EC in kidneys are penetrated with holes (fenestrated 
endothelium), while liver EC are featured with ragged junctions and wrapped in a poorly formed 
underlying basement membrane (discontinuous or sinusoidal endothelium) 8-10.  
The advances of cell biology in the 1970s allowed successful culture expansion and 
characterization of pure EC from human umbilical veins, acronymed HUVEC, which have since 
been used as a standard tool for in vitro investigation of EC functions 11-14. Subsequent 
immunohistochemical studies further discovered that subtypes of isolated EC are characterized 
by different molecular markers 15-18. For instance, Weibel-Palade bodies are highly concentrated 
in aortic EC compared with capillaries. Additionally, micro- and macro-vascular EC from various 
tissues displayed not only tissue-specific responses to stimuli in vitro but also differential protein 
expression, suggesting that the distinct molecular signatures and functions are retained in the 
absence of their original microenvironments 19,20. More recently, Nolan and colleagues carried 
out a comprehensive molecular profiling of capillary EC isolated from nine different organs 21. 
Employing a method that involves “intravital labeling” of blood vascular EC by intravenous 
injection of antibodies against endothelial markers, they isolated microvascular EC through flow 
sorting and characterized these organ-specific EC subpopulations with microarray profiling. 
Their findings demonstrate that EC express unique, organotypic clusters of transcription factors, 
angiocrine factors, adhesion molecules, and chemokines that are consistent with their functions 
in a specific organ. Furthermore, regeneration after tissue injury in different organs also elicits 
divergent angiocrine responses in different vascular beds. For example, bone marrow and liver 
EC express higher levels of ETS-family transcription factors that are crucial in EC development 
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and homeostasis compared to other EC subpopulations. Known EC markers such as Vegfr2 
and Cdh5 levels are lowest in bone marrow-derived EC compared with other EC types, whereas 
certain growth factors such as hepatocyte growth factor are markedly up-regulated only in liver 
EC, not bone marrow EC, during injury-induced regeneration.  
Because of the vastly diverse roles of EC in the growth, repair, and homeostasis of 
virtually every organ in the body, it is not surprising that EC evolve to take on tissue-specific 
characteristics. It is yet to be ascertained, however, what microenvironmental cues direct EC 
specialization and how these tissue-specific traits are maintained and transmitted. To determine 
the molecular mechanisms that control endothelial heterogeneity and to examine endothelial 
functions pertaining to a specific tissue or organ, it is therefore important to isolate and culture 
EC types derived from the tissue of interest. Although current EC isolation methods have been 
improved significantly, researchers still encounter the same difficulties associated with the 
isolation procedure as those early investigators did more than 40 years ago, primarily due to 
tenacious contaminations of non-specific cell types. Part of this thesis (Chapter 1) will attempt 
to address this problem by outlining in detail a cloning-ring method that has consistently 
produced highly pure EC cultures in our laboratory.  
In addition to heterogeneity, EC also display remarkable adaptability and plasticity. In 
intact post-developmental vessels, the endothelium generally remains quiescent. However, 
under certain physiological or pathological conditions, such as pregnancy, inflammation, or 
tumor growth, EC can be activated by angiogenic signals, such as bFGF and VEGF. They 
proliferate and initiate sprouting and subsequent angiogenesis to repair or support new tissue 
growth. They secrete an array of angiocrine factors that stimulate leukocyte infiltration and 
instigate stem cell-mediated regeneration 22. Moreover, EC are able to transdifferentiate into 
other cell types under both physiological and pathological conditions. During development, 
definitive adult-type hematopoietic stem cells emerge from the ventral aspect of the dorsal aortic 
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endothelium through a novel cell transition 23. Time-lapse fluorescence confocal microscopy 
reveals that individual aortic EC adopted a strong “bending” configuration and bulged out into 
the sub-aortic space before transiting into hematopoietic cells 24. Endothelial-mesenchymal 
transition, or EndMT, is another type of cellular process that EC undergo to generate stromal 
cells during heart valve formation. EndMT can be re-activated in diseases like tumors and 
fibrosis, where EC may revert to an embryonic-like stage and acquire stem cell-like features, 
transdifferentiating into a variety of mesenchymal cell types. A more comprehensive review of 
EndMT in both health and disease will be addressed in the later sections of this chapter.  
Tumor endothelial cells (TEC) 
TEC are essential in every step of tumor progression. Tumor cells cannot survive 
beyond the size of 1 – 2 mm3 without blood supply, and many tumors remain dormant until an 
angiogenic switch is triggered to recruit and generate blood vessels. Metastasis frequently 
requires close EC-tumor cell interaction: metastatic cells first need to escape the primary sites 
through intervasation and then extravasate at a distant site to establish metastases. In fact, 
clusters of metastatic cells are often found in close proximity to the endothelium and TEC are 
critical in promoting tumor stem cell growth and tumor progression 25. For instance, TEC in 
lymphomas secrete an angiocrine factor Jag1, which activates the Notch signaling pathway and 
downstream Hey1 transcription activities, promoting the expansion of aggressive and 
chemoresistant tumor stem cell pools 26. In a melanoma model, tumor cells treated with 
quiescent EC-conditioned media showed a slower growth curve and lower metastatic burden in 
both tail-vein injection and xenograft tumor models, compared with the tumor cells stimulated 
with media from activated EC (i.e., with an inflammatory phenotype), suggesting a pivotal role of 
the vascular niche in modulating tumor progression 27.  
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Observing these indispensable roles of the vasculature in tumor growth, Folkman in 
1971 proposed a novel way to kill tumor cells by targeting tumor blood vessels, and later 
pioneered the development of anti-angiogenic therapy 11. Since its inception, many anti-
angiogenic drugs primarily targeting VEGF-modulated angiogenic signaling and TEC 
proliferation have been developed, including a monoclonal antibody bevacizumab (Avastin) 
against VEGFR2, a VEGF-trapping antibody, and tyrosine kinase inhibitors 28. However, clinical 
benefit to prolong cancer patient survival has been limited due probably to either intrinsic 
refractory or acquired resistance of the tumor vasculature 29. In fact, studies in recent years 
have revealed that under the influence of an aberrant tumor microenvironment, tumor 
vasculature deviates from its normal counterparts in morphology, function, gene expression, 
and angiocrine signaling, which may contribute to the development of anti-angiogenic therapy 
30. Tumor blood vessels are often distended, tortuous, leaky, and absent of the normal vascular 
hierarchy 31. Tumor vasculature being constantly stimulated by angiogenic and inflammatory 
factors display a hyper-angiogenic phenotype, up-regulating proangiogenic factors such as 
VEGFRs, EPH receptors and ephrins, and endoglin 32-35.  
Characterization of isolated TEC or tumor cell-conditioned EC further revealed that these 
cells acquire inheritable genetic and epigenetic alterations. For example, Hida and colleagues 
found that TEC isolated from melanoma and liposarcoma xenografts exhibited aneuploidy and 
multiple centrosomes 36. TEC grew more rapidly and were more sensitive to growth factors like 
bFGF and epidermal growth factor (EGF) than their normal counterparts 36. Comparison of 
normal EC (NEC) and TEC isolated from human prostate tumors showed an epigenetic 
signature of hypermethylation in the GSTP1 and RARβ2 promoters in TEC 37. Microarray 
profiling of tumor-conditioned EC identified 81 down-regulated genes in TEC, and further 
examination of a subset of these gene promoters suggested that histone modification by histone 
deacetylases (HDACs) was responsible for the gene silencing 38,39. Here we also describe in 
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Chapter 3 that TEC isolated from mammary tumors express distinct gene signatures, which are 
persistent even after prolonged culturing and multiple passages, suggestive of aberrant 
epigenetic modifications in these cells. 
Another significant feature of TEC is that they acquire stem cell- or progenitor-like 
plasticity. TEC attain a high proliferative potential that shortens their doubling time to 2.4 – 13 
days, a rate that is 20 – 2000 times faster than quiescent NEC 40. Studies of TEC isolated from 
high-metastatic melanomas (HM) showed that these TEC expressed higher levels of stem-cell 
markers such as Sca-1 and CD90 compared to those from low-metastatic tumors 41. These HM-
TEC were highly proliferative and motile, and could differentiate into bone-like cells. Similar 
observations were also made by Dudley and colleagues showing freshly isolated prostate TEC 
not only had a mesenchymal-cell morphology, but also were able to dedifferentiate into cells 
that resembled mesenchymal stem cells (MSC) 42. Like MSC, these prostate TEC when induced 
by osteogenic media formed calcification and up-regulated bone markers such as osteopontin 
and osteocalcin. Condrogenenic medium, on the other hand, stimulated the differentiation of 
these TEC into cartilage-like cells which were stained positive for the cartilage dye Alcian blue, 
and  which also expressed cartilage-specific genes including Col2a1 and Sox9. Observation of 
EndMT in tumors further supports the idea that the tumor endothelium can revert to its 
developmental stage, gaining stemness and plasticity 42-44. Together, these data suggest that 
TEC are highly adaptable to their environment. They proliferate to form new vessels, change 
their secretion profiles to orchestrate tumor growth and metastasis, and even assume new 
identities in response to environmental cues. Such abilities of TEC may give rise to a highly 
adaptable tumor vasculature resembling “moving targets” that can consistently evade anti-
angiogenic treatment 30. 
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Endothelial-mesenchymal transition (EndMT) 
EndMT is critical in cardiac valve development  
EndMT, a term coined to distinguish it from a closely related cellular event called 
epithelial-mesenchymal transition (EMT), defines a process where EC lose endothelial identity 
and gain mesenchymal characteristics 45. Individual transitioning EC may detach from the 
endothelium, migrate into sub-endothelial interstitia, and transdifferentiate into mesenchymal-
like cell types. One of the most well characterized EndMT phenomena is the formation of 
cardiac cushions and subsequent cardiac valves and septa during heart development (Figure 1-
1). The heart tube formed in the early embryo (around embryonic day 9.5 in mice) consists of an 
inner endothelial cell layer and several myocardial layers on the outside 46. The endocardium 
initiates EndMT first by secreting an acellular substance called cardiac jelly into the interstitial 
space to create swellings known as cardiac cushions. A subset of EC in the endocardium are 
then activated and stimulated by TGFβ2 and TGFβ3 and other signaling pathways to undergo 
EndMT. These EC detach from the endocardium, migrate towards the underlying cardiac jelly, 
transiently up-regulate the contractile protein alpha smooth muscle actin (SMA), and 
transdifferentiate into mesenchymal cells to populate the cardiac septa and valve interstitium 47.  
Using a Tie2cre:ROSA26R-LacZ lineage-tracing model, two groups have independently 
demonstrated that cardiac valve interstitial cells derive from the EC of the endocardial cushions 
48. Approximately 5-10% of fetal valve EC co-express both SMA and the endothelial marker 
CD31, and 1% of the post-natal valve EC retain this feature, suggesting that a subpopulation of 
mature valve EC continue to possess the ability to undergo EndMT by which the valve interstitial 
cells may be replenished throughout adulthood 49.  Another interesting observation is that these 
valve EC are highly heterogeneous. EC clones isolated from adult cardiac valves exhibit 
differential responsiveness to TGFβ: some acquire SMA expression, whereas others do not 
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even after prolonged TGFβ exposure 50. While removal of serum and bFGF from the media can 
also trigger EndMT, VEGF addition was reported to counteract TGFβ-induced EndMT 50,51. A 
proportion of the clonal-derived mitral valve EC can be induced to undergo osteogenic and 
chrondrogenic differentiation, but some other clones isolated from the same valves and non-
valve EC from carotid arteries are relatively less responsive to osteogenic signals 52. Taken 
together, these data suggest that valve EC are heterogeneous in nature, and a subpopulation of 
the EC in the mature valves retains stem cell features. This mesenchymal differentiation 
potential can be reactivated under conducive environmental conditions. However, it remains 
elusive why some EC have a higher propensity for EndMT than others, and what regulates the 
differential responses in these EC subpopulations is not known. 
Pathological activation of EndMT in tumors and other diseases 
Tumors 
EndMT in tumors was first reported by Zeisberg and colleagues in their landmark studies 
of endothelial-derived fibroblasts in melanoma and pancreatic tumors. Using a lineage-tracing 
model Tie2cre:ROSA26R-LacZ the group showed that EndMT-derived tumor fibroblasts 
contributed to a mixture of heterogeneous stromal fibroblasts, which accounted for more than 
40% of total cancer-associated fibroblasts, or CAF 44. Interestingly, the investigators discovered 
that TEC differentiated into types of CAF: 30% of TEC-derived (i.e. β-gal+) tumor stromal 
fibroblasts expressed fibroblast-specific protein-1 (FSP-1), and another 12% were positive for 
SMA, suggesting that different types of EndMT may exist in tumors. Confocal 
immunofluorescence microscopy of human pancreatic tumors also revealed that endothelial 
marker CD31+ co-localized with several mesenchymal markers including SMA, SM22α, N-
cadherin, and FSP-1 53. Such transition to a mesenchymal phenotype in pancreatic tumors can 
be triggered by loss of either Tie1 or endoglin in the endothelium 53,54. 
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Our work, as discussed extensively in Chapter 4, has shown that clonal TEC isolated 
from the same tumor type were heterogeneous: some possessed mesenchymal features and 
expressed high basal levels of myofibroblast marker SMA, whereas others resembled NEC and 
expressed little to low levels of basal SMA. These different TEC subpopulations responded 
differently to the EndMT inducer, TGFβ. SMA-high EC further up-regulated myofibroblast 
markers after TGFβ stimulation, but SMA-low EC were relatively resistant to TGFβ. To quantify 
EndMT in vivo, we employed a high-fidelity endothelial lineage-tracing model Cdh5Cre: 
ZsGreenl/s/ which faithfully labels EC upon tamoxifen induction. However, we observed that in 
mammary and lung tumors approximately 0-25% of microvessels contained TEC undergoing 
EndMT per field examined. These SMA+ TEC in tumors are uncommon and often are isolated 
individuals away from the tumor microvessels, as observed by us and others 55. We also found 
that the frequency of EndMT varied in different tumor types and tumor models. For example, K-
RasG12D lung tumors and C3-TAg mammary tumors had much higher percentages of 
transitioning TEC compared with the orthotopically implanted mammary tumors.  
Although multiple groups have observed EndMT in tumors, to what extent EndMT 
contributes to the CAF population is still a matter of debate. One concern is that the endothelial 
lineage-tracing model Tie2cre:ROSA26R-LacZ used in earlier EndMT studies is not entirely 
endothelial specific and labels a proportion of bone-marrow cells, which have been shown to 
give rise to 20-40% SMA+ CAF in pancreatic tumor and gastric tumor models 56,57. Furthermore, 
CAF markers used to identify transitioning TEC are often expressed by other stromal cells 
juxtaposed with EC. For example, SMA is detected in perivascular cells including vascular 
smooth muscle cells (SMC) and pericytes, and the latter are also positive for another CAF 
protein, vimentin. This could greatly affect the accuracy of EndMT detection in vivo. Unbiased 
fluorescence-activated cell sorting (FACS) using a high-fidelity, dual-reporter mouse model 
labeling both EC and SMA+ cells (e.g. Cdh5Cre(ERT2): ZsGreenl/s/: dsRedSMA) may be used to 
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better estimate EndMT frequency in different tumor types in future studies. Nevertheless, the 
percentage of TEC that are undergoing EndMT could also be underestimated in in vivo studies, 
as snapshots of tumors of a specific time point are often used to quantify EndMT in vivo. EndMT 
may also be a dynamic process influenced by the tumor stage and microenvironment, and TEC 
may assume an intermediate type vacillating between the endothelial and mesenchymal 
phenotypes during tumor progression, which may produce varying numbers of transitioning EC 
at specific stages of a tumor.  
Despite the caveats of the in vivo models described above, EndMT has been 
unequivocally confirmed in vitro from detection of co-expression of both mesenchymal and 
endothelial markers in primary TEC or NEC challenged with	TGFβ 42,55,58-60. These in vitro 
studies have found that TEC acquire the plasticity and multipotency of stem cells, and can be 
induced to differentiate into many cell types. Studies of tumor-endothelium interaction have 
shown that EndMT promotes transmigration of melanoma cells through a TEC monolayer, 
suggesting that EndMT may play a role in tumor metastasis 58. In fact, loss of endoglin, an 
inhibitory regulator of TGFβ signaling, induces EndMT in a spontaneous pancreatic tumor 
model, Rip1-Tag2, and facilitates metastatic seeding in the liver due to a weakened endothelial 
barrier 54. In addition, transitioning TEC could also serve as a source of growth factor such as 
VEGF for stromal cell proliferation 55.  
In our studies as outlined in Chapter 4, we identified two subpopulations of mammary 
TEC: one which transitions into myofibroblast-like cells by up-regulating SMA and other 
myofibroblast markers after TGFβ challenge, and another which is relatively less responsive to 
TGFβ, suggesting that a proportion of TEC may be resistant to EndMT and this characteristic 
persists in culture (Figure 1-1).  Other groups have also observed the same phenomenon in 
different EC types.  Ishisaki et al. reported a heterogeneous EC population that contained two 
different types of cells: fast-differentiating cells that responded to TGFβ and transitioned into 
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mesenchymal-like cells in a short time, and slow-differentiating cells that required more than 
twice the length of TGFβ stimulation 60. Different endothelial TGFβ responsiveness is similarly 
confirmed in aortic valve EC 50. Some clonal valve EC respond to TGFβ treatment by up-
regulating SMA, an effect that can be blocked by a soluble TGFβR2 antagonist. Other clonal 
populations do not respond to TGFβ, but increase SMA expression only after serum withdrawal, 
which is an effect independent of TGFβ pathway activation, as addition of TGFβR2 antagonist 
does not reverse the elevated SMA. These results together indicate that heterogeneous EC 
subtypes may have distinct regulatory mechanisms of EndMT. Understanding the mechanisms 
that control this difference between the two TEC subpopulations may help map out the 
regulatory pathways of myofibroblast differentiation and design specific inhibitors that target 
CAF in tumors. 
Fibrotic diseases  
Fibrosis featured by excessive scarring tissue is a common theme in chronic diseases of 
many organs. Characteristics of fibrotic diseases include loss of normal epithelial function and 
tissue architecture, increased collagen deposition, enhanced inflammatory reaction, and 
persistent presence of SMA+ stromal cells, or myofibroblasts 61. Similar to CAF in tumors, 
myofibroblasts perpetuate epithelial injury and aggravate fibrotic tissue formation by exerting 
contraction force, secreting excessive extracellular matrix (ECM), and recruiting immune cells. 
EndMT is believed to contribute to myofibroblast generation in a variety of fibrotic conditions 
affecting the kidneys, lungs, and heart. 
EndMT has been observed in different renal fibrosis models including obstructive 
nephropathy, diabetic nephropathy, and the Alport (COL4A3 deletion) disease mouse models 62-
64. Using co-staining of an endothelial marker CD31 with the mesenchymal markers FSP-1 or 
SMA for identification of endothelial-derived fibroblasts, Zeisberg et al. reported that FSP-
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1+/CD31+ cells accounted for 25-60% of all FSP-1+ fibroblasts, and SMA+/CD31+ 36-45% of all 
SMA+ fibroblasts in kidney fibrosis. In another diabetic renal fibrosis study, 10-24% of SMA+ 
fibroblasts during the early stage of fibrosis development were of endothelial origin 65, 
suggesting that EC are significant contributors of kidney fibrosis.  
Endothelial-derived fibroblasts have also been identified in a bleomycin-induced lung 
fibrosis mouse model that carries an endothelial lineage-tracing Tie2cre:LacZ reporter 66. EndMT 
is reported to contribute to two subpopulations of fibroblasts, of which ~ 85% were COL1-
positive, and ~ 15% both COL1 and SMA positive, suggesting that EC may undergo different 
types of EndMT in fibrosis. Furthermore, elevated Ras signaling potentiates TGFβ-stimulated 
mesenchymal gene expression and induces persistent EndMT phenotype upon TGFβ 
withdrawal both in vitro and in vivo, implicating that a secondary change in the signaling network 
augments TGFβ sensitivity of the endothelium and is required for irreversible fibroblast 
differentiation. Inflammation can also sensitize the endothelium in intestinal fibrosis, where pro-
inflammatory factors, such as IL-1β and TNFα, work in synergy with TGFβ to drive EndMT 67. 
In addition, EndMT has been described in myocardiac infarction (MI) and cardiac 
fibrosis. Induction of Wnt signaling in subepicardial EC after an acute MI is associated with 
mesenchymal transdifferentiation of these cells, a result supported by in vitro observations in 
that induction of canonical Wnt pathway in cultured EC instigates EndMT 68. In a diabetic 
cardiac fibrosis model described by Widyantoro et al., hyperglycemia induced EndMT through 
up-regulation of endothelin, and EC-specific deletion of endothelin ameliorated cardiac fibrosis 
and suppressed EndMT 69. Interestingly, endothelin augments TGFβ expression in diabetic 
hearts and in cultured EC treated with high glucose, thereby activating TGFβ signaling. TGFβ 
stimulation also significantly enhances endothelin mRNA production by almost three-fold, 
suggesting a reciprocal regulatory loop of endothelin and TGFβ in the induction of EndMT. 
Similar to renal fibrosis, two different endothelial-derived fibroblast populations labeled by FSP-1 
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or SMA are identified in pressure-overload cardiac fibrosis using Tie1cre:LacZ reporter mice, and 
EndMT-derived cells contribute to 27 – 35% of the total fibroblast population 70. Activation of 
EndMT in cardiac fibrosis may be mediated by various signaling and transcription regulators, 
such as Toll-like receptor (TLR)5 and p53 71,72. Deletion of either of these factors can attenuate 
interstitial fibroblast accumulation by lessening EndMT in pressure-overload cardiac fibrosis.  
Generation of fibroblasts through EndMT in pressure overload-induced cardiac fibrosis, 
however, was questioned by Moore-Morris and colleagues in a recent study where they utilized 
multiple lineage-tracing reporter models to investigate the origins of fibroblasts in pressure 
overload-induced cardiac fibrosis 73. The authors used a Wt1cre:Col1a1-GFP:ROSA-tdT double 
reporter line to specifically label epicardial-derived fibroblasts, and a Tie2cre:Col1a1-GFP:ROSA-
tdT line to lineage trace endocardial-derived fibroblasts. They showed that these two lineages 
contributed to the generation of a vast majority of resident cardiac fibroblasts (~95%) in an 
uninjured heart during development. Transaortic constriction in adult mice induced pronounced 
accumulation of cardiac fibroblasts both in ventricular myocardium and perivascular regions of 
large coronary vessels. However, the percentages of the fibroblasts derived from the epicardium 
or endocardium remained relatively constant in this pressure overload-induced cardiac fibrosis 
model, demonstrating that resident fibroblasts, not other cellular sources, are responsible for 
fibrosis formation. Furthermore, the investigators observed that the endothelial-lineage tracing 
Tie1cre labeled non-specific immune cells which were also positive for FSP-1, which is a marker 
used to identify cardiac fibroblasts in a previous study by Zeisberg et al., where the Tie1cre:LacZ  
line was employed to show massive de novo generation of fibroblasts from mature EC through 
EndMT 70.  
Although these results by Moore-Morris et al. do not entirely exclude the occurrence of 
EndMT in pressure overload cardiomyopathy, they suggest that the contribution of EndMT may 
not be as significant in cardiac fibrosis as previously considered. However, the discrepancies in 
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these studies could be due to differences in mouse genetic background (e.g., FVB/N or 
C57BL/6 70 vs. Black Swiss 73), age of the animals (e.g., 12 – 24 weeks old 70 vs. 8 – 10 weeks 
old 73), or length of the surgery, as all these factors can potentially influence cardiovascular 
outcomes post-injury 74,75. Nevertheless, EndMT in many other fibrotic diseases has been 
supported by a considerable amount of evidence, suggesting that the frequency of EndMT may 
vary in different disease settings. These studies further demonstrated that fibroblasts are a 
highly heterogeneous population that originates from many lineages. Multiple markers specific 
for fibroblasts and myofibroblasts, such as COL1, SMA, and platelet-derived growth factor 
(PDGF) α, and highly endothelial-specific inducible cre lines, such as Cdh5cre/ER, should 
therefore be utilized in future studies to accurately determine the frequency of EndMT in fibrosis.  
Vascular diseases  
EndMT may contribute to arteriosclerotic plaque formation by promoting neointimal 
hyperplasia, which in turn can drive the progression of numerous vascular conditions, including 
pulmonary hypertension 76,77, vascular graft failure 78,79, and artherosclerosis 80. In addition, 
EndMT may play an important role in the development of venous stenosis of the liver in 
idiopathic portal hypertension 81. Increased serum TGFβ levels or perturbation of TGFβ 
signaling in these vascular disorders probably triggers EndMT, whereas inflammation and 
oscillatory shear stress during the disease progression can further boost EndMT and accelerate 
atherogenesis 78,80. TGFβ signaling leads to downstream activation of SMAD2/3 pathway in the 
atherosclerotic endothelium, whereas suppression or deletion of SMAD2 and SMAD3 lessens 
neointimal formation 79.  
Cerebral cavernous malformation (CCM), which is mainly manifested as vascular 
dysplasia in the brain, is a genetic condition caused by the loss-of-function mutations in one of 
the three CCM genes 1, 2, or 3 82. The symptoms of CCM patients include irregular and 
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enlarged vascular lesions that can lead to severe cerebral hemorrhage. Recent evidence 
strongly suggests that the pathological manifestations of both familial and sporadic CCM are a 
direct consequence of EndMT 83. Loss of the Ccm1 gene in mice promotes EndMT through 
decreasing EC markers and up-regulating a panel of mesenchymal genes, leading to cerebral 
vascular leakage and dysplasia 84. Although the pathogenesis of CCM is not entirely clear, it is 
believed that Ccm1 deficiency elevates BMP6 production, which acts synergistically with TGFβ 
to trigger SMAD-mediated EndMT 85.  
Complex signaling networks regulate EndMT 
TGFβ signaling  
TGFβ is the single most important EndMT inducer. Three TGFβ isoforms (types 1, 2, 
and 3) that share a similar peptide structure have been identified. They belong to the TGFβ 
superfamily that comprises more than 30 ligands categorized into six subgroups, including 
TGFβs and other members consisting of activins/inhibins, nodals, BMPs, growth differentiation 
factors, and Mullerian inhibiting substance 86. TGFβ is synthesized as a homodimeric proprotein 
that contains an N-terminal pro-peptide region, termed as the latency-associated peptide (LAP), 
and a C-terminal polypeptide region. Intracellular proteolytic cleavage of LAP from the TGFβ 
proprotein produces the mature TGFβ peptide, which forms an inactive complex with LAP. This 
inactive TGFβ complex is sequestered by latent TGFβ binding proteins (LTBP) and deposited 
into the ECM upon secretion 87. Subsequent activation of TGFβ requires mobilization of the 
TGFβ peptide from the ECM by proteases or thrombospondin regulated by complex signals in 
response to ECM damage or other extracellular perturbations 88. All three TGFβs bind to the 
same receptors and activate them through similar mechanisms; however, local ligand 
availability and receptor affinity may determine their differential biological effects during 
development 89.  
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Seven type I receptors and five type II receptors for the TGFβ superfamily ligands are 
found in humans, and ligand binding induces formation of a receptor complex comprising of two 
type I and two type II components, all of which are serine/threonine kinases. Once released 
from ECM, TGFβ peptides bind to the type II receptor TGFBR2, which then recruit and activate 
the type I receptor TGFBR1 (or anaplastic lymphoma kinase 5 [ALK5]) to induce downstream 
signaling 90. The signal strength depends on differential ligand affinity for TGFBR1 and 
mediation of co-receptors including endoglin and betaglycan (TGFBR3) 91,92.  
TGFβ signaling is intricately complex and highly cellular-context dependent. Its outcome 
is influenced by cell type, microenvironment, interaction with other signaling pathways and 
transcription factors, epigenetic landscape, and innate genetic variations 86,93. Many different 
downstream signaling factors can be activated by TGFβ, including the canonical transcription 
factors, SMADs, and other non-SMAD mediators. In vertebrates, there are eight SMADs: six 
receptor-activated SMADs (R-SMADs), a common SMAD (Co-SMAD) named SMAD4, and two 
inhibitory SMADs (I-SMADs) which include SMAD6 and SMAD7 94. R-SMADs 2 and 3 are 
predominantly activated by TGFβ binding of TGFBR1, whereas R-SMADs 1, 5, and 8 are 
phosphorylated mainly by BMP-regulated activation of other receptors such as ALK1, ALK3, 
and ALK6. Activated R-SMAD dimerizes and binds to SMAD4 before nuclear translocation. I-
SMADs, on the other hand, can bind to R-SMADs to block their transcription activation ability. 
TGFβ also regulates gene expression by SMAD-independent pathways, including Ras-mediated 
ERK, p38 MAPK, PI3K/Akt, and Rho-like GTPase signaling 95.  
TGFβ-stimulated EndMT was first observed in cultured bovine aortic EC in the early 
1990’s 96. The induction of EndMT by TGFβ was later confirmed in vivo by Brown and 
colleagues, who reported that neutralizing TGFβ signaling with a TGFβR2 blocking antibody 
blocks the activation of EndMT during cardiac cushion development. 97. In pathological 
conditions, aberrant increase of TGFβ due to inflammation and tissue injury can trigger EndMT 
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by activating both SMAD-dependent and SMAD-independent pathways 27,98,99, but contribution 
of each of these pathways in EndMT may be context-dependent. In this thesis project, we have 
found that TGFβ mediated EndMT in mammary tumor EC through both SMAD2/3 and PI3K 
signaling, and blocking of these pathways attenuated TGFβ activity (Chapter 4). Activation of 
SMAD and non-SMAD signaling can in turn lead to transcriptional up-regulation of EndMT 
master transcription factors such as Snail, Slug ZEB-1, SIP-1, Twist, and LEF-1, which then 
allow the induction of mesenchymal genes and suppression of endothelial genes 99,100.  
Other regulatory pathways can also interact with TGFβ signaling to either augment or 
inhibit EndMT. For instance, TGFβ coordinates with several BMPs and Notch signaling to 
synergistically stimulate mesenchymal gene expression in valve EC during cardiac valve 
development	46. Induction of EndMT in cultured HUVEC has been shown to require synergistic 
action of IL1β and TGFβ, although only TGFβ is necessary for sustaining mesenchymal gene 
expression 101. Depletion of an inhibitory co-receptor endoglin sensitizes EC to TGFβ stimulation 
and promotes EndMT in tumors, while a TGFβ superfamily member BMP7 antagonizes TGFβ-
induced EndMT both in vitro and in vivo 54,70,102. In addition to BMP7, tyrosine kinase receptor 
ligands such VEGF and bFGF have been shown to counteract TGFβ signaling and reverse 
EndMT in normal valve EC and the arteriosclerotic endothelium respectively 51,78. This thesis 
work has also found that bFGF, but not VEGF, acts as a potent inhibitor of EndMT, completely 
blocking TGFβ-stimulated myofibroblast gene induction in EC isolated from mammary tumors. 
(More on bFGF and TGFβ interaction will be discussed in the following section.) Together, these 
studies suggest that TGFβ mediates EndMT in a context of complex signaling network, and its 
effect is likely controlled by an array of diverse factors including EC heterogeneity, 
microenvironment, and activation state of other signaling pathways.  
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bFGF 
FGFs are a pleiotropic group of ligands that signal through four highly conserved 
receptor tyrosine kinases (RTKs), FGF receptors (FGFRs) 1 – 4. They regulate a plethora of 
major cellular processes during development, ranging from early embryonic mesoderm 
patterning to the formation of multiple organ systems 32-35,103. In EC, FGFR1 and FGFR2 are the 
most predominant isoforms, and upon ligand binding they dimerize and autophosphorylate to 
activate downstream signaling cascades. A total of 18 distinct mammalian FGFs have been 
discovered, among which the prototype FGFs, acidic fibroblast growth factor (aFGF) and bFGF, 
are particularly critical in early endothelial specification and vascular development 104.  
aFGF and bFGF share 55% sequence homology and they exert similar biological effects 
on many different cell types, although their signal strength depends on the expression of 
subtypes and splice variants of FGFRs and on the ligand-receptor affinity 105. In particular, bFGF 
is well known for its potent pro-proliferative and angiogenic effect on EC. Cultured mesoderm 
cells cannot differentiate into endothelial progenitors in the absence of bFGF 106. bFGF is also 
pivotal in the maintenance of endothelial VEGFR2 expression that is indispensable in VEGF-
stimulated angiogenesis 107. In mature vasculature post development, endothelial-specific FGF 
signaling is essential in injury response, as endothelial deletion of both FGFR1 and FGFR2 
significantly delays wound healing of the skin and impairs hypoxia-induced angiogenic response 
in the retina 108.  
In addition to regulating EC functions, emerging evidence shows that bFGF signaling 
intersects with TGFβ pathways to influence downstream cellular events during EndMT. High-
throughput screenings of 60 different combinations of ECM proteins singled out bFGF as the 
strongest negative regulator of TGFβ-induced EndMT 109. Other studies reported that bFGF 
decreased TGFβR1 levels and reversed the growth inhibitory effect of TGFβ1 on EC 110. bFGF 
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directly blocks TGFβ-induced EndMT in arteriosclerotic lesions, whereas suppression of bFGF 
signaling through inflammation-mediated FGFR1 down-regulation renders EC prone to EndMT 
78. In lymphatic vessels, bFGF inhibits EndMT and maintains lymphatic EC identity by opposing 
TGFβ-activated SMAD2 through Ras/ERK MAPK signaling 111. bFGF also decreases TGFβ-
stimulated SMA and mesenchymal gene expression in pericytes and airway SMC 112,113. The 
close bFGF homologue, aFGF, acts similarly to bFGF to counteract TGFβ signaling. Deprivation 
of aFGF or TGFβ stimulation, for example, induces mesenchymal genes SM22 and calponin in 
HUVEC, while treatment with aFGF blocks TGFβ-induced gene expression and decreases the 
acquired SMC-like contractility 60. This antagonistic effect of aFGF on TGFβ, transduced 
through the MAPK/ERK pathway, is also observed in fibroblasts and in epithelial cells during 
EMT 114-116.  
The antifibrotic effect of bFGF is additionally demonstrated by studies of hypertrophic 
scars and keloid tissue formation during wound healing, where bFGF effectively deceased 
collagen production, ECM proteins, and SMA expression in fibroblasts through suppressing 
SMAD-dependent pathways 117. More remarkably, administration of bFGF evidently reduced 
scar tissue and inhibited the profibrogenic effect of TGFβ in in vivo wound-healing models and 
in clinical studies, indicating that the therapeutic benefits of bFGF are likely due to inhibition of 
myofibroblast generation 118-121.  
An intriguing reciprocal interaction between TGFβ and bFGF is also discovered by this 
thesis work in that TGFβ treatment of EC can induce bFGF production and secretion, which 
inhibits TGFβ signaling in these same cells (Chapter 4). Conditioned media harvested from 
TGFβ-stimulated EC contained high levels of bFGF, which suppressed mesenchymal gene 
induction and preserved endothelial markers in a fresh batch of EC induced to undergo EndMT. 
In agreement with our findings, studies by others have also confirmed that bFGF expression is 
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enhanced by TGFβ in human lung fibroblasts, and this secreted bFGF can in turn activate ERK 
pathway through autocrine activation of its own receptors 122. 
Surprisingly, bFGF is also implicated in the promotion of EMT, and in some instances, 
EndMT. Studies of avian heart development suggested that both TGFβ and bFGF are inducers 
of EMT of the epicardium during coronary vasculogenesis 123. Isolated epicardial cells in 
response to the combination treatment of bFGF and TGFβ increased motility and proliferation, 
and penetrated the underlying matrix, which is a characteristic of EMT. In a different study 
where the epicardial-lineage cells were generated from human pluripotent stem cells, addition of 
bFGF augmented TGFβ-stimulated expression of mesenchymal markers including SMA and 
vimentin, although bFGF-induced proliferation and expression of EMT transcription factor SNAI1 
were counteracted by TGFβ 124. Similarly, bFGF is shown to induce EndMT in corneal EC 125,126.  
These conflicting results may be due to a number of reasons. First, bFGF signaling, like 
TGFβ pathways, is highly complex and cellular-context dependent. Intrinsic factors such as cell 
heterogeneity and extrinsic factors such as culture conditions may influence cellular responses 
to bFGF. Distinctive cell types and tissue may also respond to bFGF differently. The second 
compounding issue is that the hallmarks and markers of EndMT and EMT are not precisely 
defined, and studies on EndMT and EMT often use different readouts (gene expression, cell 
shape, motility). Such diverse characterization methods may lead to different interpretations and 
conclusions in different studies.  
In addition, it is possible that bFGF acts synergistically with TGFβ as a fibroblast 
mitogen, promoting myofibroblast proliferation after mesenchymal transition is triggered by 
TGFβ, rather than a profibrogenic initiator that works concurrently with TGFβ in EMT or EndMT. 
Such temporal interaction between bFGF and TGFβ has been demonstrated in the studies of 
paraxial mesoderm myogenesis during chick embryonic development 127. The investigators 
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showed that a two-step mechanism likely occurred during myogenesis: pulse exposure of TGFβ 
was required to initiate myogenesis at the early stage of myogenesis, whereas bFGF, albeit not 
necessary for myogenic commitment, was indispensible in maintaining long-term cell survival 
and proliferation. These data suggest that time-sensitive regulation of bFGF may be important in 
myofibroblast generation. It is therefore conceivable that bFGF may have a biphasic effect on 
EMT or EndMT: counteracting the pro-differentiation effect of TGFβ signaling at the initiation 
stage, but promoting myofibroblast growth once the mesenchymal differentiation pathway is 
committed.  
Other signaling pathways 
Various other pathways have also been implicated in EndMT. BMP7 inhibits EndMT 70,81, 
whereas BMP6 acts synergistically with TGFβ to activate EndMT through SMAD1/3-dependent 
pathways in CCM 84,85. Studies by different groups have also reported the importance of Wnt-β-
catenin signaling in EndMT. Mice with endothelial-specific deletion of β-catenin fail to develop 
heart cushion due to impaired EndMT during development 128, but in adult cardiac EC injury-
triggered canonical Wnt signaling activation leads to the initiation of EndMT in myocardiac 
infarction 68. In a CCM mouse model, loss of Ccm3 gene triggers Wnt-independent β-catenin, 
which initiates EndMT in the cerebral vasculature 129, indicating that β-catenin can dynamically 
regulate EndMT depending on the cell context. Depletion of Tie1 can also induce EndMT by up-
regulating the EndMT transcription factor Slug through ERK1/2, ERK5, and Akt cascades 53. 
Moreover, hypoxia-stimulated HIF1 pathway, which is a major regulator of EMT, has been 
shown to contribute to EndMT activation in many fibrotic diseases 130-135.  
MicroRNAs (miRNAs) in EndMT 
miRNAs have recently emerged as important new players in EndMT, and they regulate 
mesenchymal gene expression and EndMT signaling through depletion of a single gene or 
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several target genes. Global perturbation of miRNA levels has been observed during 
pathological EndMT 136. Based on their roles, EndMT-associated miRNAs can be categorized 
into two groups: pro-EndMT and anti-EndMT miRNAs. Pro-EndMT miRNAs antagonize 
inhibitory regulators, thereby up-regulating EndMT signaling. Examples include miRNA-21, 
which promotes EndMT by activating Akt pathway through silencing of a phosphatase and 
tensin homolog in EC 137. miR-342-5p is another EndMT inducer which initiates EndMT probably 
by down-regulating endoglin, a TGFβ signaling inhibitor 138. On the other hand, anti-EndMT 
miRNAs frequently target positive regulators to curb profibrotic signaling and mesenchymal 
gene expression. An aforementioned miRNA regulated by bFGF, let-7, for example, maintains 
endothelial identity by counteracting TGFβ signaling, whereas reduced let-7 expression by 
disruption of bFGF signaling activates EndMT 78. Another miRNA, miR-125b, can suppress 
profibrotic signals in cardiac EC by down-regulation of p53 136. Decreased miR-200b levels have 
been observed during EndMT in diabetic hearts, and over-expression of miR-200b reverses 
high glucose-activated EndMT by suppressing multiple TGFβ downstream targets in cardiac EC 
139.  
Impact of pathological EndMT 
The significance of EndMT in tumors and other diseases is multifold. First, EndMT 
serves as a cellular source for CAF in tumors or myofibroblast in fibrotic diseases. CAF are 
activated fibroblasts in tumor stroma identified by the expression of the prototypical marker 
SMA, and they promote tumor progression by supporting primary tumor growth and stimulating 
tumor metastasis 140. Similarly, myofibroblasts in fibrotic diseases can exacerbate fibrotic 
conditions through multiple mechanisms, including disrupting normal ECM and sustaining 
inflammatory response, which lead to loss of organ functions 61. Secondly, vascular function and 
integrity may be affected by transitioning EC detaching and migrating away from the 
endothelium. For example, EndMT contributes to enhanced endothelial permeability and 
	 24	
abnormal vascular morphology of the cerebral vasculature in CCM 69,84, while in tumors 
increased metastasis may result from EndMT 54,58. Alteration of endothelial functions may also 
contribute to parenchymal hypoxia, leading to detrimental consequences in hypoxia-sensitive 
organs such as the kidney 141. Thirdly, aberrant endothelial signaling as a result of EndMT may 
promote tissue inflammation, and cause dysregulated angiogenesis and abnormal angiocrine 
profiles. Finally, loss of endothelial markers, especially VEGFR2 which is an anti-angiogenic 
target in the treatment of late-stage tumors, during EndMT could potentially facilitate the evasion 
of anti-angiogenic therapies.  
Another aspect of EndMT shown collectively by us and others using different disease 
and lineage tracing models is that EC are heterogeneous and respond to TGFβ differently. 
Subsets of EC can transition into distinct fibroblast subpopulations with distinctive molecular 
markers, for example, COL1+ or SMA+ fibroblasts. Our results showed that only a proportion of 
mammary TEC transdifferentiate into SMA+ myofibroblast-like cells in response to TGFβ, 
whereas other TEC do not. It has been recently proposed that in tumors CAF are a polarized 
cell type consisting of tumor-restricting (Type I) and tumor-promoting (Type II) populations 140. 
While Type I CAF are SMA- and inhibit tumor growth, Type II CAF are activated fibroblasts that 
up-regulate an array of mesenchymal markers including FSP-1, vimentin, PDGF receptor 
(PDGFR) β, and the prototypical myofibroblast marker SMA. In fact, acquisition of SMA 
expression, or myofibroblast contractility, determines cell fate and function during mesenchymal 
stem cell differentiation 142. However, it is unclear what regulates the heterogeneity of CAF and 
their precursors, and why some precursor cells are resistant to TGFβ challenge and remain 
SMA-. Furthermore, mechanisms that reverse or inactivate myofibroblast gene expression 
during EndMT are not well defined. It also remains elusive if different subpopulations of CAF 
derive from a common or different ancestors, and if these CAF subtypes are interconvertible. 
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Future studies that delineate the molecular mechanisms that regulate these processes will 
facilitate the design of targeted therapies for cancer and fibrosis treatment. 
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Figures 
Figure 1-1. EndMT in development and disease.  
EC undergo EndMT during cardiac valve formation in development. In certain pathological 
conditions such as fibrosis and tumors, EC can respond to TGFβ and other inflammatory factors 
to transdifferentiate into myofibroblasts. The endothelium consists of a heterogeneous 
population: some EC are less responsive to TGFβ, whereas other cells are highly responsive to 
TGFβ stimulation and readily transition into an intermediate mesenchymal cell type that express 
both endothelial and mesenchymal markers. These responder EC may eventually differentiate 
into myofibroblasts, which can drive disease progression in both fibrosis and tumors. 
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Table 
Table 1-1. Common endothelial markers expressed in mature blood and lymphatic 
vasculature. 
Markers Blood EC Lymphatic EC Other cell types/tissues 
CD31 (PECAM-1) 143 + + Megakaryocytes, subsets of B 
and T lymphocyte, monocytes, 
neutrophils 
CD34 73,144  Heterogeneous + Fibroblasts; hematopoietic cells 
CD144 (VE-Cadherin 
or Cadherin 5 
[CDH5]) 145  
+ + Popliteal lymph node sinus 
macrophages 
Claudin 5 146-148 +; more 
concentrated in the 
blood-brain barrier 
and endoneurial 
blood-nerve barrier 
+ Pancreatic acinar cells, alveolar 
lung cells, intestinal epithelium 
E-selectin 149-151 Proliferating or 
inflammatory 
endothelia 
Activated 
lymphatic EC 
 
EPH receptor B4 152 Venous EC -  
Ephrin B2 152 Arterial EC -  
Factor VIII 153 Heterogeneous - Platelets, megakaryocytes 
Friend leukemia 
integration 1 
transcription 
factor (FLI1 or ERGB) 
144 
+ - Lymphocytes 
LYVE-1 153 - + Macrophage marker Mac-1-
positive cells 
Podoplanin 153 - + Nerve sheaths, lingual gland 
myoepithelial cells 
PROX1 154,155  - + Renal papilla 
Scavenger receptor 
type 1 (DiI-Ac-LDL 
uptake) 154  
+; higher in capillary 
EC 
+ Smooth muscle cells, 
macrophages 
Stem-cell antigen 1 
(Sca-1) 6,156  
Heterogeneous, 
possibly endothelial 
progenitor cells 
- Hematopoietic stem cells, 
stem/progenitor cells in other 
organs, perivascular cells 	
TIE-1 157,158 +; stronger in 
arterial EC 
+ Hematopoietic stem cells 
TIE-2 159 + + Monocytes and macrophages 
VCAM 160 Inflammatory 
endothelia 
-  
VEGFR1  15,161  + - Monocytes, vascular SMC, 
hematopoietic cells, retina	
VEGFR2 161-166 + + Retina, neural stem/progenitor 
cells 
VEGFR3 167 Fenestrated blood 
endothelia 
+  
von Willebrand factor 
144,168 
Heterogeneous - Megakaryocytes, platelets, 
plasma 
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CHAPTER 2: Isolation and Long-Term Culture Expansion  
of Tumor-Specific Endothelial Cells1,2 
Overview 
Freshly isolated TEC can be used to explore molecular mechanisms of tumor 
angiogenesis and serve as an in vitro model for developing new angiogenesis inhibitors for 
cancer. However, long-term in vitro expansion of murine endothelial cells is challenging due to 
phenotypic drift in culture (EndMT) and contamination with non-EC. This is especially true for 
TEC which are readily out competed by co-purified fibroblasts or tumor cells in culture. Here, a 
high fidelity isolation method that takes advantage of immunomagnetic enrichment coupled with 
colony selection and in vitro expansion is described. This approach generates pure endothelial 
cell fractions that are entirely free of contaminating stromal or tumor cells. It is also shown that 
lineage-traced Cdh5cre:ZsGreenl/s/l reporter mice, used with the protocol described in this 
chapter, are a valuable tool to verify cell purity as the isolated EC colonies from these mice 
show durable and brilliant ZsGreen fluorescence in culture.  
																																																								1This chapter is modified from a previous publication which appeared in the Journal of Visualized 
Experiments.  The original citation is as follows: Xiao, L., McCann, J. V., & Dudley, A. C. Isolation and 
culture expansion of tumor-specific endothelial cells. JoVE (Journal of Visualized Experiments), (104), 
e53072–e53072. http://doi.org/10.3791/53072. (2015). 
 2Reprinted with permission from the journal Journal of Visualized Experiments.	
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Introduction 
EC are essential during the development of solid tumors. From initiation of the 
angiogenic switch in dormant tumors to dissemination and seeding of metastases at distant 
sites, EC form the conduits that provide blood, oxygen, and nutrients to sustain tumor growth 1. 
As suggested by recent studies, EC also have perfusion-independent functions and form a 
niche that supports the growth of cancer stem cells and other tumor stromal cells by releasing 
angiocrine factors 2-5. Thus, highly purified TEC for in vitro culture allows for routine functional 
studies that will shed light on novel molecular mechanisms mediating tumor angiogenesis and 
tumor/stromal cell-to-EC cross talk.  
EC are highly specialized depending on the tissue of origin 6. Due to the heterogeneous 
nature of different tumor types and the tumor microenvironment, TEC may also display unique 
features that reflect a tumor-specific specialization of the vasculature. For example, there is 
striking variability in the gene expression signatures in TEC isolated from different types or 
grades of tumors 7,8. However, frequent co-purification of non-EC, especially tumor-associated 
fibroblasts and tumor cells, with TEC can confound genome-wide expression analyses. These 
unwanted cell types are especially problematic in studies that rely on long-term in vitro 
expansion of TEC cultures. 
Described here is a high-fidelity method that consistently produces pure EC cultures 
from tumors and other tissues. Following immunomagnetic column enrichment of EC fractions 
and removal of co-purified non-EC, an additional cloning-ring step to capture pure EC colonies 
is used 9. Each colony can be expanded in culture for multiple passages without the emergence 
of contaminating non-EC. This method also yields multiple EC clones from a single isolation 
procedure, which is ideal for the study of endothelial heterogeneity. In addition, it is shown that 
Cdh5cre:ZsGreenl/s/l reporter mice are a valuable tool for generating “fate-mapped” and indelibly-
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marked EC which maintain ZsGreen fluorescence in culture 10. With minor adjustments to the 
protocol, this method should be adaptable to different tumor types or normal tissues. 
Results 
EC represent only a minor fraction of the total cell population in most adult tissues 11. It is 
therefore important to fully digest the harvested tissue into a single-cell suspension that ensures 
the maximal release of EC from ECM and connective tissues. In our experience, CD31-
mediated immunomagnetic selection only provides enriched but not pure EC fractions; 
therefore, another crucial step is the physical removal of co-purified non-EC and 
selection/expansion of EC colonies using cloning rings (Figure 2-1). However, when column 
eluates were plated at low density, the EC colonies grew with relatively few surrounding non-
EC, which were removed by scraping with a pipet tip (Figure 2-2B). The growth and purity of the 
expanded colonies can be further monitored by addition of Dil-Ac-LDL. Small EC colonies can 
be observed at ~ Day 7 after CD31-mediated column enrichment of EC (Figure 2-2B, top 
panels).  
To test if the isolation method can produce consistent results, multiple clones derived 
from either mammary tumors resected from C3-TAg (FVB/N C31-TAg) mice or normal mammary 
glands from age-matched wild-type FVB mice were isolated and expanded 12. C3-TAg female 
mice develop spontaneous mammary intra-epithelial neoplasia at ~ 12 weeks of age which 
resembles human ductal carcinoma in situ, and at ~ 16 weeks of age tumors progress to 
palpable, well-vascularized, invasive carcinoma 13. Comparison of normal mammary gland of 
wild-type mice and mammary tumors of C3-TAg mice are shown in Figure 2-3 (a-b). CD31 
immunohistochemistry of normal mammary gland and mammary tumors shows numerous 
CD31+ blood vessels (Figure 2-3A, c-d). 
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Each isolated TEC and NEC population was carefully characterized to ensure purity. 
Flow cytometry analyses of three independent samples showed a single, uniform CD31+ 
population that was distinct from IgG isotype controls (Figure 2-3B). The mRNA expression of 
EC markers, including Cd31, Cdh5 (VE-Cadherin), Cd133, and Vegfr2 in all four EC clones 
tested was ~ 200 to 7000 times higher than that of mouse embryonic fibroblasts (MEFs) which 
was used as a negative control (Figure 2-3C). As expected, all EC clones expressed nearly 
undetectable levels of the mesenchymal marker genes Col1a1 and Tagln when compared to 
MEFs. None of the EC expressed the SV40 large T-antigen (T-Ag) carried by C3-TAg mice 
(Figure 2-3D), thus ruling out a tumor cell of origin for TEC. Furthermore, immunofluorescent 
staining showed that all cells in a representative TEC clone were uniformly CD31+ (Figure 2-
4A), and these EC clones were able to form spontaneous vessel-like structures in vitro, 
indicating they retain endothelial functions after culturing (Figure 2-4B). 
The isolation method was further validated using Cdh5cre:ZsGreenl/s/l mice where all EC 
are indelibly labeled with the green fluorescent protein, ZsGreen (Figure 2-5A, a). Lung tissue 
that contains abundant EC was used as proof-of-principle for the isolation procedure (Figure 2-
5A, b). ZsGreen+ cells comprised ~ 30% of the total cell population in the lung homogenate, and 
were partially enriched after CD31-mediated immunomagnetic column selection(Figure 2-5B). 
As Cdh5cre:ZsGreenl/s/l mice carry a constitutive cre gene, a proportion of hematopoietic cells are 
also labeled with ZsGreen 10. Thus, the actual EC percentage in the lungs may be lower than 
the observed ~ 30%. Notably, approximately 20% of cells co-isolated with ZsGreen+/CD31+ EC 
were ZsGreen- (Figure 2-5B). Since contamination by these non-EC may persist in culture, the 
enriched EC population at this stage is not suitable for studies that require further in vitro cell 
culture. However, after applying cloning rings to capture pure EC colonies, one hundred percent 
pure ZsGreen+ population was obtained that could be further expanded in culture(Figure 2-5C 
and 4D).  
	 46	
Discussion 
Due to the difficulties in obtaining pure primary TEC cultures, many in vitro studies 
substitute TEC with commercially available EC lines or primary EC such as human umbilical 
vein EC (HUVEC) 14. However, these EC populations from normal tissues may only serve as a 
proxy for TEC which differ markedly from their normal counterparts. For example, TEC are 
phenotypically and functionally abnormal in vivo and some of these abnormalities may be 
transmittable in vitro 15-19. TEC have aberrant growth, migratory, and differentiation abilities and 
may coalesce with CD31+ tumor cells to form vessel-like structures 17,20,21. Studies using either 
cultured TEC or laser capture micro-dissected tumor vessels have demonstrated that TEC 
deviate from normal EC in gene expression, cytogenetic, and epigenetic profiles 12,19,22-24. 
Despite deepening our understanding of tumor angiogenesis over the past few decades, very 
few functional and mechanistic studies using cultured primary TEC are available.  
The first successful EC isolation from human umbilical veins was established in the early 
1970s 25. Subsequent isolation and culturing of microvascular EC from other human and mouse 
tissues has provided a powerful tool for the investigation of endothelial function in both health 
and disease 26-29. Most EC isolation protocols involve three major steps: obtaining a single-cell 
suspension after mechanical dissociation or enzymatic digestion, labeling EC with an 
endothelial-specific antibody that is conjugated to either a fluorophore or magnetic microbeads, 
and enriching the EC population using cell sorting or magnetic columns. However, isolation of 
mouse EC, especially from tumors, has proven difficult due to the low yield of viable EC and 
frequent contamination of other cell types including tumor cells and fibroblasts. In addition, in 
vitro phenotypic drift of EC into mesenchymal-like cells (EndMT) poses an additional challenge 
for long-term culturing of EC from normal tissues, tumors, and reprogrammed progenitors 30.  
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A major challenge during TEC isolation is contamination by tumor cells, which can easily 
outcompete the slower-growing EC colonies that typically appear after ~ 7 to 10 days in culture. 
In addition, a commonly used selection marker for isolating EC is CD31 which is abundantly 
expressed in the endothelium but also marks hematopoietic cells and in some cases tumor cell 
subpopulations 21,31. Furthermore, while enriching for EC, CD31-mediated immunomagnetic 
column selection cannot remove every single contaminating cell that will eventually take over 
EC cultures after a few passages. By adding a cloning-ring step, it is possible to select and 
expand pure clonally-derived EC populations that are free of these contaminating cell types. A 
second challenge is the long-term maintenance of pure EC without promotion of EndMT. 
EndMT occurs during development, may be recapitulated during vascular dysfunction, and is 
common in cultured EC (especially in the presence of TGFβ) 32-34. To minimize EndMT, remove 
contaminating cells that may act as a source TGFβ, keep cultures at high densities, and 
maintain high concentrations of bFGF in the media at all times. As shown in Chapter 4 of this 
thesis, bFGF is essential to preserve EC specification as it antagonizes TGFβ-driven expression 
of SMA 35.  
Using this methodology, isolation of EC from “fate-mapped” reporter mice was also 
shown. These mice are particularly useful in studies where intravital imaging is needed 36. 
Although some labeling of hematopoietic cells may occur in the Cdh5cre:ZsGreenl/s/l mice used 
here, this model provides a relatively rapid and easy method for generating fluorescent EC in 
vivo. An alternative EC lineage-labeling model is a tamoxifen-inducible mouse (Cdh5cre/ERT2) 
which, when crossed with a floxed reporter mouse strain such as ZsGreenl/s/l, will have only EC 
faithfully and irreversibly marked 37,38. Fluorescent EC from the inducible cre mice may also be 
purified using FACS or the methodology we describe in this chapter.  
EC are heterogeneous across different vascular beds and “intra-vessel” heterogeneity 
may also exist among EC within the same vessel 39,40. As cloning-ring selection of EC colonies 
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gives rise to multiple clonal subpopulations, this method can be useful for functional and genetic 
profiling of EC subtypes that exist within tumors and other tissues 12. Taken together, described 
here is an EC isolation method that produces pure EC colonies devoid of contaminating non-
EC. The isolated cells should be useful for in vitro functional studies, genome-wide expression 
profiling, and molecular characterization of new pathways to inhibit tumor angiogenesis.  
Experimental Procedures 
As the EC isolation protocol developed and validated here in this study requires close 
attention to details, a comprehensive, step-wise procedure is outlined below.  
1. Prepare the following material and reagents before starting 
Prepare EC media by supplementing 400 mL low glucose (1 g/L D-glucose) DMEM with 50 
mL fetal bovine serum, 50mL Nu-Serum IV, 5 mL antibiotic-antimycotic, and the hFGF, 
VEGF, hEGF, R3-IGF-1, and heparin components from the EGM-2 bullet kit. The following 
protocol is carried out according to guidelines established by the Department of Laboratory 
Animal Medicine at the University of North Carolina at Chapel Hill. 
2. EC Isolation (Day 1, ~ 5 hrs) 
2.1) Spray mouse with ethanol and resect tumors with one pair of scissors and dissectors 
using aseptic techniques in a sterile hood and place in 30 mL of LG-DMEM on ice. 
2.2) Bring samples to tissue culture hood; wash tissues with sterile LG-DMEM 1 – 2 times.  
2.3) Place tumors in 2 mL of LG-DMEM in a sterile petri dish, and mince with a pair of sterile 
scissors into pieces < 5 mm.  
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2.4) Add 5 mL of collagenase (stock = 2 mg/mL in HBSS), 1 mL of dispase (stock = 2.5 U/mL 
in HBSS) and 75 µL of DNase (stock = 1 mg/mL in PBS) into a tube. Total volume is 
now ~ 10 mL.  
2.5) Add the collagenase-tissue mix to tube and run on a tissue dissociator. 
2.6) Incubate with light shaking for 75 min at 37 °C.  
2.7) Filter digested tissue through 100 µm cell strainer over a 50 mL conical tube. Rinse filter 
with 5 µL of FACS buffer to wash any remaining cells.  
2.8) Spin at 280 x g for 5 min and carefully aspirate the supernatant without disturbing the 
cell pellet.  
2.9) Dilute 1 mL of stock RBC lysis buffer (10X) in 9 mL of sterile water. Lyse red blood cells 
with 10 mL of lysis buffer (1X), and immediately spin 5 min at 280 x g. (This step can be 
skipped if little blood is visible.)  
2.10) Resuspend in 10 mL of FACS buffer and count cells.  
2.11) Resuspend cells at ~107 cells/100 µL.  
2.12) Add 10 µL of Fc block per 100 µL of cell suspension, and incubate on ice for 10 min.  
2.13) Add rat-anti mouse PE-conjugated CD31 antibody according to Table 2-1. Incubate on 
ice for 10 – 15 min and flick tube occasionally.  
2.14) Add 10 mL of FACS buffer to the tube and spin at 280 x g for 5 min. Carefully remove 
the supernatant, and wash the cell pellet again with 5 mL of FACS buffer. Centrifuge to 
pellet cells. Aspirate supernatant without disturbing cell pellet. 
2.15) Add FACS buffer and anti-PE microbeads according to Table 2-2. 
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2.16) Incubate on ice for 10 - 15 min. Flick tube occasionally. 
2.17) Add 10 mL of FACS buffer and spin samples at 280 x g for 5 min; wash once with 5 mL 
of FACS buffer and centrifuge again. Aspirate supernatant without disturbing pellet. 
2.18) Bring volume to 300 µL in FACS buffer.  
2.19) Spin through 35 µm cell-strainer capped tube 5 min at 280 x g. Use 2 tubes and a larger 
volume if needed. 
2.20) Set up magnetic multistand and magnetic columns in hood, attach a column to the 
separator and equilibrate the column with 2 mL of FACS buffer. 
2.21) Aspirate and resuspend the cell pellet in 0.5 mL - 1 mL of FACS buffer. 
2.22) Pass the cell suspension through the equilibrated magnetic column. 
2.23) Wash the column three times with 2 mL of FACS buffer, and collect flow-through (FT) in 
a tube (FT fraction). 
2.24) Take the column off the separator and elute with 2 mL of FACS buffer into another 
falcon tube (eluate fraction). Use plunger to ensure all cells are off the column. Repeat 
the elution two more times with 2 mL of FACS buffer each time. 
2.25) Spin the eluate at 280 x g 5 min. 
2.26) Remove the supernatant and resuspend the pellet in 10 mL of EC media. 
2.27) Plate FT and eluate fractions in 10 cm gelatin-coated dishes. (Important: The cells need 
to be plated sparse so that EC colonies can form without being contaminated by other 
cell types. For three 1 cm3 tumors, plate eluted cells in at least four plates. Alternatively, 
plate eluted cells at different concentrations to ensure that cells are sparsely plated.) 
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2.28) Freeze down the FT faction in the next few days. 
2.29) Change media every 2 - 3 days and colonies start to form after 7 - 10 days. Small EC 
colonies can be identified as early as Day 3. Mark the colonies with a marker on the 
bottom of the dish. 
2.30) Scrape off non-specific cells surrounding the identified colonies with a pipette tip every 
day. If possible, let colonies expand to 3-5 mm in diameter before harvesting, but do not 
let EC colonies grow beyond Day 14. 
3. Colony selection using cloning rings 
3.1) Change media every 2 – 3 days. EC purity can be checked by LDL (DiI-Ac-LDL) addition 
at about 5 – 7 days. Add 50 µL of LDL per 10 mL EC medium to the cells and incubate 
for 3 – 4 hrs before checking the cells under fluorescence microscope.  
3.2) Multiple LDL+ EC clones can be observed at ~ Day 7. Start harvesting EC colonies when 
they reach diameters of 3 – 5 mm in size. (Choose big colonies that are packed with 
small LDL+ cells for best results.) 
3.3) Before harvesting EC with cloning rings, pre-coat a few 6-well plates with 0.5% gelatin. 
Aspirate gelatin, add 2 mL of EC media to each well, and keep the plates in an incubator 
until needed.  
3.4) Scrape off non-EC on the edges of the colonies to make sure no other cell types will be 
trapped within the cloning ring.  
3.5) Using a light microscope, outline with a marker on the bottom of the culture dish the 
areas containing EC-colonies.  
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3.6) Wash the plate with 10 mL of PBS and leave a very thin layer of PBS in the plate when 
aspirating. (Important: a small amount [~ 0.5 mL] of PBS will keep cells alive during the 
cloning-ring procedure; also, tissue adhesive needs water to bond.)   
3.7) Choose a cloning ring of appropriate size. Use a pair of dissecting forceps to pick up a 
ring, and with a 10 µL pipet tip evenly apply a small amount of tissue adhesive onto the 
cloning ring. (Important: use only minimal amount [~ 0.2 µL for a small ring] of tissue 
adhesive on cloning rings, and make sure tissue adhesive is spread out evenly around 
the bottom surface to ensure good sealing. Excessive tissue adhesive produces heat 
and forms films that may kill cells.)  
3.8) Place the cloning ring over the EC colony. Gently press down the cloning ring to glue the 
ring onto the plate. (Important: make sure the colonies are not dried out before gluing the 
ring.)  
3.9) Immediately pipet 25 µL of enzymatic cell detachment solution into the cloning ring and 
incubate ~ 1 min or until the cells are loosely attached.  
3.10) Pipet cells in the cloning ring drop-wise into one well of a 6-well plate containing pre-
warmed EC media. (Important: do not shake the plate to disperse cells; EC prefer to 
grow in tight clusters.) Wash the cloning ring with 50 – 100 µL EC media to collect as 
many cells as possible, and transfer all washes into the same 6-well.  
3.11) If some colonies in the 10 cm dish are too small to harvest, add 10 mL fresh media, let 
the colonies grow for a few more days, and repeat the cloning ring procedure. 
3.12) Grow harvested colonies in 6-well plates until 80-100% confluent, and transfer cells to 3 
wells of a 6-well plate before expanding them in a 10 cm tissue culture dish. Scrape off 
contaminant cells. Repeat another round of cloning ring procedure (Steps 2.5 – 2.10) if 
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necessary. Keep cells relatively confluent (~ 60-70% confluency) when expanding. EC 
may stop growing if plated too sparse. 
3.13) Characterize EC by FACS, staining, PCR, etc. Note that Dil-Ac-LDL is fluorescent and 
may interfere with PE or other fluorescent antibodies for FACS. 
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Figures 
Figure 2-1. Schematic diagram of the EC isolation procedure.  
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Figure 2-2. Dil-Ac-LDL distinguishes EC from contaminating non-EC in live cultures.  
(A) Phase contrast and fluorescent images showing EC and co-isolated non-EC without cloning-
ring selection of EC colonies. (B) Phase contrast and fluorescent images of EC colonies at 
different stages of isolation. Dotted lines mark the boundaries of Dil-Ac-LDL+ EC and 
surrounding contaminating cells. White arrowheads indicate non-EC outside an EC colony that 
should be removed with a pipette tip. Scale bars represent 100 µm. 
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Figure 2-3. Cloning rings and physical removal of non-EC produce EC cultures.  
(A) Normal mammary glands from wild-type mice and mammary tumors from C3-TAg mice (a-b) 
and their corresponding CD31 staining (c-d) reveals vascular structures. White arrowheads 
indicate the tissues resected for EC isolation. Black scale bar is 10 mm; white scale bar is 10 
µm. (B) Representative FACS dot plots of CD31 staining of different EC clones. Three 
representative samples are shown. The open black rectangle in each plot outlines the CD31+ 
population. An IgG isotype is used as a negative control. (C) Measurement of endothelial gene 
expression in selected NEC and TEC clones. The mRNA levels of endothelial genes Cd31, 
Cd133, Cdh5, and Vegfr2 are expressed relative to those of mouse embryonic fibroblasts 
(MEFs), and the mRNA levels of mesenchymal genes Col1a1 and Tagln are expressed relative 
to those of NEC-1. (D) Western blot of SV40 large T-antigen carried by C3-TAg mice indicating 
the absence of T-antigen protein in NEC and TEC cultures. 
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Figure 2-4. Expanded EC cultures retain endothelial marker CD31 and endothelial 
function in vitro.  
(A) Representative immunofluorescent staining of an expanded TEC clone. CD31 is shown in 
green and nuclei are stained blue with DAPI. (D) Representative images of tube formation by 
different EC clones plated on Matrigel. Scale bars represent 100 µm. 
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Figure 2-5. EC isolated from Cdh5cre:ZsGreenl/s/l mice maintain brilliant ZsGreen 
fluorescence in culture.  
(A) The endothelial-lineage tracing mouse Cdh5cre:ZsGreenl/s/l carries a floxed ZsGreen 
transgene that is induced by Cdh5cre expressed by EC. (a) Lung tissue from the 
Cdh5cre:ZsGreenl/s/l mice were harvested and digested for EC isolation. (b) Representative 
images of Cdh5cre:ZsGreenl/s/l mouse lung tissue. ZsGreen (green) labels the endothelium and 
nuclei are stained with DAPI (blue). (B) FACS dot blots showing the percentages of ZsGreen+ 
cells before (middle panel) and after (right panel) the CD31-mediated column enrichment from 
the homogenized lung tissue of a Cdh5cre:ZsGreenl/s/l mouse. Unstained wild-type (WT) lung 
homogenate (left panel) was used as a negative control for gating. The large open rectangles 
indicate ZsGreen- cells and the small open rectangles indicate cells double positive for ZsGreen 
(FL1-H channel) and CD31 (FL2-H channel). (C) FACS histogram plot showing that ZsGreen+ 
EC (green peak) remain 100% pure after in vitro culturing. A ZsGreen- EC population was used 
as a negative control (gray peak). (D) Representative phase contrast and fluorescent images of 
an early-stage ZsGreen+ EC colony and an expanded ZsGreen+ EC colony. Scale bar 
represents 100 µm. 
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Tables 
Table 2-1. PE-conjugated anti-CD31 antibody volumes required for different cell numbers. 	
Table 1 
Cell number FACS buffer (µL) CD31-PE antibody 
(µL) 
1X107 100 5 
2X107 200 6 
3X107 300 7 
4X107 400 8 
5X107 500 9 
6X107 600 10 
 
Table 2-2. Anti-PE microbead volumes required for different cell numbers. 	
Table 2 
Cell number FACS buffer (µL) Anti-PE magnetic 
microbeads (µL) 
1X107 80 20 
2X107 160 40 
3X107 240 60 
4X107 320 80 
5X107 400 100 
6X107 480 120 
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CHAPTER 3: Identification of a Stable Molecular Signature in Mammary Tumor 
Endothelial Cells that Persists In Vitro3,4 
Overview 
Long-term, in vitro propagation of TEC allows for functional studies and genome-wide 
expression profiling of clonally-derived, well-characterized subpopulations. Using a genetically 
engineered mouse model (GEMM) of mammary adenocarcinoma, we have optimized an 
isolation procedure and defined growth conditions for long-term propagation of mammary TEC. 
The isolated TEC maintain their endothelial specification and phenotype in culture. Furthermore, 
gene expression profiling of multiple TEC subpopulations revealed striking, persistent 
overexpression of several candidate genes including Irx2 and Zfp503 (transcription factors), 
Alcam and Cd133 (cell surface markers), Ccl4 and neurotensin (Nts) (angiocrine factors), and 
Gpr182 and Cnr2 (G protein-coupled receptors, GPCRs). Taken together, we have developed 
an effective method for isolating and culture-expanding mammary TEC, and uncovered several 
new TEC-selective genes whose overexpression persists even after long-term in vitro culture. 
These results suggest that the tumor microenvironment may induce changes in vascular 
endothelium in vivo that are stably transmittable in vitro. 
																																																								3This chapter is modified from a previous publication appeared in Angiogenesis.  The original citation is 
as follows: Xiao, L., Harrell, J. C., Perou, C. M., & Dudley, A. C. Identification of a stable molecular 
signature in mammary tumor endothelial cells that persists in vitro. Angiogenesis, 17(3), 511–518. 
http://doi.org/10.1007/s10456-013-9409-y (2014). 	4Reprinted with permission from the journal Angiogenesis.	
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Introduction 
Vascular EC are highly specialized in order to meet the metabolic demands of specific 
tissues. For example, a recent study demonstrated that isolated, organ-specific EC express 
combinations of factors unique to each organ 1. Moreover, transplanted “generic” EC acquire 
specific features of the organ in which they occupy 1. These studies suggest that EC are 
remarkably malleable and “tuned” to conditions found in the surrounding microenvironment. In 
tumors and other pathophysiological states, the endothelium may also be modified or educated 
by specific microenvironmental cues. Indeed, most tumors are typified by hypoxia, acidosis, and 
the presence of inflammatory cytokines to which the endothelium must adapt. Multiple studies 
have described unique gene expression patterns in freshly isolated TEC from different tumor 
types which may reflect either a transient adaptive response or stable reprogramming due to 
epigenetic modifications 2,3. 
A challenge to better understanding the biology of the tumor vasculature is that it is 
difficult to isolate and maintain a homogeneous population of TEC for long-term, in vitro 
expansion. But as we have shown, clonally-derived TEC may be propagated in culture and 
further characterized using functional in vitro assays 4-6. On one hand, ex vivo propagated TEC 
may no longer resemble TEC in situ once they are removed from influences of the tumor-
microenvironment. For example, it is well-known that tissue-specific EC undergo genetic drift in 
culture and lose expression of key factors 7-10. On the other hand, TEC which are immediately 
processed following isolation cannot be further characterized in vitro nor can individual 
subpopulations of TEC be studied 11,12. Moreover, it is difficult to ensure that TEC isolated by 
methodologies such as laser capture micro-dissection or fluorescence-activated cell sorting are 
entirely free of contaminating tumor cells or perivascular cells which can confound genome-wide 
expression profiling studies.  
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Using a GEMM of mammary adenocarcinoma (C3-TAg) we have optimized an isolation 
procedure and defined an ideal growth medium for maintaining highly-enriched, clonally-derived 
TEC populations (from the same tumor) for long-term culture. For comparison, we have isolated 
NEC from mammary glands from age-matched littermates and carried out genome-wide mRNA 
expression profiling of these different populations under identical culture conditions. Overall, we 
show that clonally-derived populations of NEC and TEC can be maintained free of tumor 
cell/stromal cell contamination, and they retain their endothelial specification. In addition, we 
have identified several new candidate genes, some of unknown function in EC, that are 
persistently up regulated in TEC cultures.	
Results 
Isolated TEC maintain the expression of endothelial-selective genes and are free of 
mesenchymal cells and tumor cells 
Using flow cytometry, we found that both NEC and TEC continued to express CD31 and 
CDH-5 during prolonged culturing (greater than 6-8 passages) (Figure 3-1A). 
Immunocytochemistry confirmed that ~ 100% of the cultured cells were CD31+ and did not 
express the mesenchymal marker SMA (Figure 3-1B, a-l). CD31 was localized at cell-cell 
junctions in NEC and TEC indicating that all primary EC maintained their endothelial features in 
vitro. To examine the gene expression profiles of EC clones and C3-TAg tumor cells, we 
performed genome-wide mRNA expression microarrays and generated a “vascular content” 
genetic signature recently described by us 13. As predicted, both NEC and TEC were enriched 
for endothelial-selective genes as defined by the “vascular content” genetic signature and when 
compared to C3-TAg tumor cells (p=0.00073) (Figure 3-1C). Hierarchical clustering and 
analysis of candidate, endothelial-selective factors demonstrate the relative difference between 
NEC, TEC, and mammary tumor cells derived from C3-Tag mice (Figure 3-1D). Furthermore, 
	 69	
the expected vascular-specific factors including Cd133, Cdh-5, Edg1, Scarf1, Cd31, eNos, Tek, 
and Esam1 were highly enriched in all TEC clones, whereas the levels of tumor cell markers, 
including several cytokeratins (Krt), were essentially absent.  
Genome-wide expression profiling reveals a distinct molecular signature in mammary 
TEC 
We next compared the gene expression profiles of TEC and NEC, represented as a 
Venn diagram, to identify differentially expressed genes (Figure 3-2A). Hierarchical clustering of 
249 differentially-expressed genes demonstrated a consistent expression pattern in NEC and 
TEC populations as indicated by the dendrogram (Figure 3-2B). The entire microarray dataset is 
available for further query (https://genome.unc.edu) and a gene list of the 20 most down-
regulated and up-regulated genes in TEC relative to NEC is shown (Figure 3-2C). A regression 
analysis using multiple NEC and TEC clones (19,619 genes) showed an overall striking 
congruency in gene expression (r=0.9641) in TEC versus NEC but multiple genes remained 
either up- or down-regulated in TEC cultures (Figure 3-2D).We used qPCR to validate eight up-
regulated candidate genes from four different functional groups identified by our microarray. On 
average, the expression of each of these genes displayed the same trend as revealed by the 
microarray (Figure 3-3A). The most dramatically up-regulated genes in TEC clones included 
Irx2, Grp182, and Ccl4, with ~ average increases of 160, 28, and 12 fold, respectively (when 
compared to NEC). However, mRNA expression of individual clones for each gene was 
variable. For example, the relative expression of Cnr2 for the three TEC clones ranged from 0.6 
– 6.5 fold, whereas Gpr182 expression ranged from 8 – 50 fold, indicating that TEC from the 
same tumor, while retaining similar gene expression profiles, may be heterogeneous in the 
expression of different factors.  
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Aberrant expression of TEC-selective genes persists in vitro 
Finally, we chose one gene from each category, and then carried out qPCR in cells at 
two time points separated by 4-5 sequential passages depending on the cell type. The results 
showed that Irx2, Ccl4, Cnr2, and Cd133 were on average persistently up-regulated in TEC 
relative to NEC, even after prolonged culturing and repeated passages (Figure 3-3B). Taken 
together, these results suggest that even after their removal from the tumor microenvironment, 
TEC retain over-expression of several candidate genes relative to their normal counterparts. 	
Discussion 
 A congruent TEC-specific genetic profile in TEC from different tumor types, or in TEC from 
the same tumor, has not been established 2. This inconsistency likely arises from the 
heterogeneous nature of EC found in different organs (and tumors) as well as limitations of TEC 
isolation methodologies which include laser capture micro-dissection and positive selection by 
magnetic columns or cell sorting. Both methods can produce highly enriched, but not entirely 
pure TEC populations. Our use of magnetic columns followed by cloning rings to capture and 
expand individual TEC colonies has proven effective for deriving long-term cultures that are free 
of perivascular cells and tumor cells.  
 Because the microarray revealed aberrant and persistent expression of multiple factors in 
TEC cultures, we propose that stable, transmittable changes are induced in TEC during tumor 
progression that are retained ex vivo. However, it will be important to confirm the expression of 
these factors in tumors in vivo, either by in situ hybridization or immunohistochemistry in tumors 
during different stages of development. We stratified the microarray analysis into four categories 
(transcription factors, angiocrine factors, cell surface markers, and GPCRs) and further 
confirmed the over-expression of two candidate genes from each category by qPCR. For 
example, the transcription factors Irx2 and Zfp503 (Nolz-1), both highly enriched in TEC, 
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regulate neural patterning and differentiation during development 14,15. Proliferating EC and 
neural precursors rely on common factors for network formation during development, and many 
of the same signaling pathways that regulate axon guidance overlap with those that control 
vessel sprouting 16. Thus, activated TEC may co-opt neuronal cues during tumor angiogenesis. 
We also identified two secreted angiocrine factors (Nts and Ccl4) that are up-regulated in TEC. 
These factors are pro-inflammatory and may stimulate leukocyte proliferation and mobilization 
that create a permissive environment for tumor growth 17. Thus, in addition to forming blood 
vessels, TEC may have perfusion-independent functions in the tumor microenvironment by 
orchestrating chronic inflammatory responses through secreted factors 18.  
 Other genes identified by our microarray include cell surface markers and GPCRs. For 
example, Cd133 was up-regulated in mammary TEC and in isolated prostate TEC as previously 
reported by us 5. Though its function is unclear, CD133 was long-considered a marker of 
endothelial progenitor cells but more recent evidence supports a role for CD133 as a marker of 
proangiogenic hematopoietic precursors 19. Similarly, ALCAM (CD166) is typically up-regulated 
on activated hematopoietic cells but is also expressed in inflamed/activated blood vessels 
where it regulates leukocyte capture and trafficking 20. Expression of the GPCRs Gpr182 and 
Cnr2 were both markedly increased in TEC. The orphan receptor GPR182, once thought to be 
the adrenomedulin receptor, has no known function in EC but is enriched in embryonic 
vasculature 21. On the other hand, CNR2 expression is well-characterized in vascular cells 
where it appears to play a role in dampening inflammatory responses and endothelial activation 
upon receptor stimulation 22,23. 
 Folkman proposed that anti-angiogenic therapies could be used to attack tumor blood 
vessels and shrink solid tumors 24. Although anti-angiogenic therapies are highly effective in 
curbing pathological neovascularization in non-malignant diseases such as wet macular 
degeneration, these same therapies have not produced a durable benefit in patients with 
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different cancers 25,26. Thus, it is possible that TEC are more diverse and complex than 
previously recognized and may not respond predictably to angiogenesis inhibition 27. Further 
characterization of TEC from different tumor types, or perhaps multiple subpopulations of TEC 
as we have done here, may reveal new vascular-selective targets for anti-angiogenic therapy 28.	
Experimental Procedures 
Mice 
C3-TAg (FVB/N C31-TAg) mice were provided by the Mouse Phase 1 Unit from the 
Lineberger Comprehensive Cancer Center at UNC Chapel Hill. Tumors were harvested under 
sterile conditions when mice were ~ 5 months of age. Normal mammary tissue was obtained 
from age-matched, wildtype littermates. 
Cell culture and media 
Isolated EC were maintained in 1 g/L D-glucose DMEM (LG-DMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS), 10% Nu-Serum IV (BD), and Lonza EGMTM-2 
SingleQuots including hFGF, VEGF, hEGF, R3-IGF-1, and heparin. Mammary tumor cells 
isolated from C3-TAg tumors were cultured in DMEM with 4.5 g/L D-glucose (Gibco) and 10% 
FBS. Mouse monocytes (M1) were purchased from ATCC and were grown in RPMI containing 
10% FBS. Mouse mesenchymal stem cells (MSC) were purchased from Gibco and were 
maintained in DMEM/F-12 (Gibco) with 10% MSC-qualified FBS (Gibco). All media were 
supplemented with antibiotic-antimycotic (Gibco). 
Endothelial cell isolation 
The EC isolation method was modified from previously published procedures 5. Briefly, 
freshly-resected tumors were minced into ~ 3 mm pieces and transferred to LG-DMEM 
containing 1 mg/mL collagenase type II (Worthington), 100 µg/mL deoxyribonuclease 
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(Worthington), and 0.25 U/mL neutral protease (Worthington) at an approximate ratio of 1 tumor 
volume to 3-5 volumes of digestion solution. The sample was homogenized on the Miltenyi 
Tissue Dissociator (Miltenyi Biotec) before being placed on a shaker at 37°C for 75 min. The 
tumor digests were then filtered with a 100 µm cell strainer to obtain a single-cell suspension 
before pelleting at 1200 rpm for 10 min. If blood was visible in the cell pellet, 10 mL of 1X 
PharmLyse B (BD Pharmingen) was used to lyse the red blood cells, and the sample was 
immediately centrifuged at 1200 rpm for 5 min. Next, the cells were resuspended in 10 mL 
MACS buffer (de-gassed phosphate-buffered saline [PBS] containing 2 mM EDTA and 0.5% 
BSA) and counted. Cells were pelleted and then resuspended in MACS buffer at 1.0 x 107 
cells/100 µL. FcR Blocking Reagent (Miltenyi) (10 µL/100 µL cell suspension) was added to the 
sample, which was then incubated on ice for 15 min. The subsequent two-step antibody 
incubation includes first adding a PE-rat anti-mouse CD31 antibody (BD Pharmingen, 553373) 
and then anti-PE microbeads (Miltenyi). Each antibody incubation step was performed on ice for 
15 min. After each antibody incubation, the cells were washed twice with MACS buffer, 
centrifuged, and resuspended in 500 µL MACS buffer. The final cell suspension was filtered 
through a 35 µm cell strainer and then passed through the magnetic Miltenyi LS Column pre-
equilibrated with MACS buffer. The column was washed three times with 2-3 mL MACS buffer 
to remove unbound cells. Bound cells were eluted with 2-3 mL MACS buffer three times. The 
eluted cells were washed with growth medium once and plated at a density of ~ 1.0 x 106 
cells/10 mL in the same medium onto 10 cm tissue-culture dishes coated with 0.5% gelatin 
(Sigma-Aldrich). The medium was changed every 2-3 days and Dil-Ac-LDL (Biomedical 
Technologies) was added to the plates to monitor the size of the EC colonies. When EC 
colonies grew to ~ 3-5 mm in diameter, LDL-negative cells surrounding the EC clones were 
lightly scraped off using a 200-µL pipette tip. Cloning rings of appropriate sizes were glued onto 
the plate using Vetbond (3M) to trap EC clones which were then washed once in PBS, detached 
with 25 µL Accutase (Sigma), and transferred into individual wells of a gelatin-coated 96-well 
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plate. Cells were slowly expanded over the next 3-4 weeks into larger wells and then 10 cm 
dishes. 
Polymerase chain reaction (PCR) and real-time quantitative PCR (qPCR) 
Primers were designed using either Invitrogen Primer Perfect Design Software or NCBI-
Primer Blast. Total RNA was isolated using an RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. cDNA synthesis was completed using an iScript cDNA Synthesis 
Kit (Bio-Rad). End-point PCR was carried out using a Taq PCR Kit (NEB) with the products 
resolved on agarose gels. qPCR was run in triplicate with Maxima SYBR Green (ThermoFisher) 
on an Applied Biosystems Step One Plus analyzer.  
Flow cytometry 
Cells were analyzed by flow cytometry as previously described using a BD Accuri® C6 
Flow Cytometer 5,6. Data were post-analyzed using FloJo (Version X). 
Immunofluorescence (IF) 
IF was carried out as previously described 5,6. Antibodies include: 1:100 rat anti-mouse 
CD31 antibody (BD, 550274), 1:200 Alexa Flour® 488 goat anti-rat antibody (Invitrogen, 
A11006), and 1:500 monoclonal mouse anti-SMA Cy3 antibody (Sigma, C6198). Slides were 
mounted with Vectashield Hardset Mounting Medium with DAPI (Vector Labs) and imaged on a 
Leica DM IRB inverted microscope.  
Gene expression microarrays and bioinformatics analysis 
All EC and tumor cells were profiled using mouse oligo gene expression microarrays 
(Agilent Technologies, Santa Clara, CA, USA) as previously described 29. Microarray data are 
available at UNC Microarray Database (https://genome.unc.edu) and have been deposited in 
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the Gene Expression Omnibus (GEO) under the accession number GSE50555. Heat maps 
were generated using the Gene-E software package 
(http://www.broadinstitute.org/cancer/software/GENE-E/). Statistical analysis for the microarrays 
was carried out with WinSTAT, R v2.15.1, Cluster v3.0, and Prism. The probes were filtered by 
requiring the Lowess normalized intensity values in both sample and control to be > 10. All 
probes for each gene were averaged. The normalized log2 ratios (Cy5 sample/Cy3 control) of 
probes mapping to the same gene (Entrez ID as defined by the manufacturer) were averaged to 
generate independent expression estimates for each gene. For each cell type the “vascular 
content” gene expression signature value was identified by averaging the normalized log2 ratio 
value for each gene within the signature 13. Sixty-six of 74 vascular content signature genes 
were present in this dataset. For the heat map contrasting array data from TEC and mammary 
tumor cells, the normalized log2 ratio values were utilized for selected genes known to be 
expressed in vascular cells. A two-class significance analysis of microarrays was utilized to 
identify NEC and TEC-specific genes (FDR<5), which were then median centered and 
hierarchically clustered. 
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Figure 3-1. Isolated TEC maintain the expression of endothelial-selective genes and are 
free of mesenchymal cells and tumor cells.  
(A) Flow cytometry plots demonstrating expression of CD31 and CDH-5 by NEC and TEC. (B) 
Representative images of CD31 (green) and SMA (red) expression in NEC and TEC. MSC were 
used as a positive control for SMA. Nuclei were counter-stained with DAPI (blue). Scale bar 
represents 10 µm. (C) Vascular content gene expression signature scores in NEC, TEC, and 
the mammary tumor cell line. (D) Hierarchical clustering and gene expression heat map 
identifies enrichment of EC-selective markers and absence of tumor cell markers (Krt) in 
different TEC clones.  
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Figure 3-2. Genome-wide expression profiling reveals a distinct molecular signature in 
mammary TEC.  
(A) Venn diagram depicting up-regulated, down-regulated, and similarly-expressed genes in 
TEC versus NEC. (B) Supervised hierarchical clustering and gene expression heat map of 249 
genes differently expressed in TEC versus NEC. (C) The 20 most down-regulated and up-
regulated genes in TEC relative to NEC. The selected genes have an FDR<5. The ID is the 
mouse Entrez Gene ID. (D) Scatter plot comparing NEC and TEC gene expression for 19,619 
genes. Each point represents the mean expression level of each gene in NEC and TEC. 
Colored dots identify 8 selected candidate genes that were up-regulated > 2-fold in TEC versus 
NEC.  
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Figure 3-3. Aberrant expression of TEC-selective genes persists in vitro.  
(A) qPCR confirmation of genes identified/selected from the microarray screen using different 
NEC and TEC clones. (B) qPCR analysis of selected genes at different time points. Depending 
on the cell type, cells were split 4-5 times between day 0 (d0) and day 10 (d10). 
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CHAPTER 4: Tumor Endothelial Cells with Distinct Patterns of  
TGFβ-Driven Endothelial-to-Mesenchymal Transition5,6 
Overview 
EndMT occurs during development and underlies the pathophysiology of multiple 
diseases. In tumors, unscheduled EndMT generates cancer-associated myofibroblasts that fuel 
inflammation and fibrosis, and may contribute to vascular dysfunction that promotes tumor 
progression. We report that freshly isolated subpopulations of TEC from a spontaneous 
mammary tumor model undergo distinct forms of EndMT in response to TGFβ stimulation. 
Whereas some TEC strikingly up-regulate SMA, a principal marker of EndMT and activated 
myofibroblasts, counterpart NEC from normal mammary glands showed little change in SMA 
expression after TGFβ treatment. Compared with NEC, SMA+ TEC were 40% less motile in 
wound healing assays and formed more stable vascular-like networks in vitro when challenged 
with TGFβ. Lineage tracing using Cdh5cre:ZsGreenl/s/l reporter mice confirmed that only a 
fraction of vessels in breast tumors contain SMA+ TEC, suggesting that not all EC respond 
identically to TGFβ in vivo. Indeed, examination of 84 TGFβ-regulated target genes revealed 
entirely different genetic signatures in TGFβ-stimulated NEC and TEC cultures. Finally, we 																																																								5This chapter is modified from a previous publication appeared in Cancer Research.  The original citation 
is as follows: Xiao, L., Kim, D. J., Davis, C. L., McCann, J. V., Dunleavey, J. M., Vanderlinden, A. K., et al. 
Tumor endothelial cells with distinct patterns of TGFβ-driven endothelial-to-mesenchymal transition. 
Cancer Research, 75(7), 1244–1254. http://doi.org/10.1158/0008-5472.CAN-14-1616. (2015). 	6Reprinted with permission from the journal Cancer Research. 
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found that bFGF exerts potent inhibitory effects on many TGFβ-regulated genes but operates in 
tandem with TGFβ to up-regulate others. EC challenged with TGFβ secrete bFGF which blocks 
SMA expression in secondary cultures suggesting a cell-autonomous or lateral-inhibitory 
mechanism for impeding mesenchymal differentiation. Together, our results suggest that TGFβ-
driven EndMT produces a spectrum of EC phenotypes with different functions that could 
underlie the plasticity and heterogeneity of the tumor vasculature.  
Introduction 
EndMT is defined as the loss of endothelial-specific factors and gain of mesenchymal 
features that accompany the morphogenesis of specific tissues, especially those of the heart 1. 
EndMT also occurs in various pathological conditions including cerebral cavernous 
malformations, cardiac and kidney fibrosis, vein stenosis, and cancer 2-7. In these diseased 
states, aberrantly regulated EndMT results in unscheduled conversion of EC into diverse 
mesenchymal-lineage cell types, especially myofibroblasts, that may dissociate from the vessel 
wall and can be found throughout the affected tissue 8-14. EndMT coincides with genome-wide 
reprogramming that allows EC to exist in a variety of phenotypic states but may also cause 
vascular dysfunction that contributes to disease progression 9,15,16. 
The concept that EC may “drift” towards mesenchymal-like cell types was shown many 
years ago in TGFβ treated EC cultures 17. TGFβ, and other members of the TGFβ superfamily, 
impart plasticity to EC by activation of specific transcription factors (e.g. Snail, Slug, and Twist) 
that interact with chromatin modifiers to create genome-wide epigenetic reconfigurations 15,18. 
Whether acquisition of the mesenchymal program in EC is a partial and transient or stable and 
transmittable change in cellular specification is not clear. The context-dependency of TGFβ, 
combined with its cell-type specific activity, has made it challenging to understand how EC react 
to sustained TGFβ signaling, particularly in complex tissues such as tumors 19,20. In addition, EC 
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responses to TGFβ may proceed differently in different types of EC owing to heterogeneous 
forms of mesenchymal differentiation throughout the vasculature that is tumor-type and/or 
tumor-stage dependent. 
Recently, we isolated normal mammary gland EC (NEC) and mammary tumor EC (TEC) 
from a transgenic tumor model 21. We were surprised to find a wide range of mesenchymal-like 
genetic signatures among these different types of EC challenged with TGFβ in vitro. 
Furthermore, whereas some TGFβ-stimulated mesenchymal genes (e.g. SMA) were blocked by 
addition of bFGF, expression of other mesenchymal genes was augmented by the combination. 
These results require a refined assessment for how EndMT is defined across different vascular 
beds. In principle, EndMT may be characterized by a spectrum of intermediate and reversible 
mesenchymal-cell phenotypes, especially in pathological tissues. Moreover, EC resist specific 
conversion to SMA+ myofibroblast-like cells when challenged with TGFβ through secretion of 
bFGF; thus, EC maintain their own fate and differentiation by a self-regulatory mechanism that 
counteracts TGFβ activity. 
Results and Discussion 
Isolation of TEC with an intermediate EndMT phenotype 
To validate the purity of isolated NEC and TEC clones from wild-type mice and spontaneous 
mammary tumors in C3-TAg mice after prolonged culturing, multiple clones were selected for 
FACS analysis of the expression of endothelial markers CD31 and CDH5. All clones uniformly 
expressed both CD31 and CDH5 (Figure 4-1A) 21. Surprisingly, a number of TEC clones 
showed elevated basal mRNA expression of the EndMT and myofibroblast differentiation 
marker, SMA (Acta2) (Figure 4-1B). On the other hand, expression of endothelial markers Cd31 
and Vegfr-2 were variable among all NEC and TEC clones and did not correlate with the levels 
of Acta2 mRNA (Figure 4-1B). When challenged with TGFβ2, TEC-H8 (a clone with high basal 
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SMA expression) up-regulated SMA protein expression, whereas an NEC clone (B12) and TEC-
A2 (a SMA-low TEC clone) were relatively unresponsive (Figure 4-2A). TEC-H8 were 
responsive to all three TGFβ isoforms and similar results were obtained using an additional 
mammary TEC clone with high SMA mRNA (TEC-D8) and mesenchymal-like prostate TEC 
previously described by us (Figure 4-2B and 2C) 8. As non-EC (e.g. SMA+ fibroblast) 
contamination can occur during EC isolation, we performed staining with SMA and CD31 to 
exclude this possibility. All individual cells in the TEC clone examined expressed CD31, and 
confocal images clearly revealed co-localization of SMA+ stress fibers and CD31 in the same 
cells post-TGFβ2 treatment (Figure 4-2D). SMA+ EC have been observed in the luminal surface 
of healthy thoracic aorta, but their density is markedly increased in atheromatous aorta 22,23. The 
appearance of SMA+ EC correlates with a pro-inflammatory state, such as in tumors or fibrosis, 
where TGFβ is also highly up-regulated 22,23. It is possible that the tumor microenvironment 
promotes the conversion of SMA- EC into SMA+ EC, or favors the enrichment of rare but pre-
existing SMA+ EC located throughout the mammary gland vasculature.  
To test whether there were any functional differences between SMA-high TEC and NEC, 
we carried out a time-lapse wound healing migration assay using TEC-H8 and NEC-B12 clones. 
NEC-B12 challenged with TGFβ2 showed little difference in migration compared to untreated 
controls whereas TEC-H8 migration was inhibited by ~ 40% (Figure 4-3A). TGFβ2 also 
markedly enhanced TEC-H8 contraction in collagen gel contraction assays, while exerting little 
effect on NEC-B12 (unpublished data, DJK). These results are consistent with previous studies 
showing impaired migration of SMA+ myofibroblasts and are perhaps related to higher 
contractility and increased focal adhesions associated with filamentous actin stress fibers 24-26. 
In contrast, formation of in vitro vascular structures was inhibited by 60-80% in NEC-B12 and 
SMA-low TEC (TEC-A2) challenged with TGFβ2 but were increased by 40% in TEC-	H8 (Figure 
4-3B).  Taken together, our data suggest that subpopulations of EC are differentially receptive to 
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TGFβ stimulation: some are characterized by high SMA induction, decreased migration, and 
stabilized vascular structures whereas others respond oppositely.  
TGFβ induces diverse genetic signatures in different types of EC 
We next used qPCR to compare the expression pattern of 12 mesenchymal marker 
genes in TGFβ2-treated NEC-B12 versus TEC-H8 cultures. Strikingly, we found the pattern of 
gene expression to be entirely opposite when these genes were hierarchically clustered (Figure 
4-4A). For example, whereas NEC-B12 strongly up-regulated mesenchymal markers including 
calponin 1 (Cnn1), transgelin (Tagln), cadherin 11 (Cdh11), and endosialin (Cd248), TEC-H8 
strongly increased the expression of Acta2 (SMA), fibronectin 1 (Fn1), Pdgfrβ, and desmin 
(Des). Basal FN1 protein expression was also slightly higher in TEC-H8 and was further 
increased after TGFβ2 stimulation as shown by Western blotting (Figure 4-S1A). Another cluster 
of mesenchymal genes including tenascin c (Tnc), endoglin (Eng), and vimentin (Vim) were 
slightly elevated in TEC-H8 and their levels were variably altered by TGFβ2 treatment. The EC 
markers Cdh5, Cd31, and Vegfr1 were either moderately decreased or unchanged by TGFβ2 
challenge. Longer periods of TGFβ2 treatment could result in sustained down-regulation of 
these and other EC-specific genes. Notably, the pericyte marker Ng2 was not detected in NEC 
or TEC-H8 with or without TGFβ2 treatment, ruling out the presence of contaminating pericytes 
in these cultures (data not shown). 
As both SMAD-dependent and SMAD-independent pathways are implicated in 
mesenchymal gene regulation during EndMT, we used pharmacological inhibitors to evaluate 
different mechanisms of TGFβ2-induced SMA expression in TEC 27. We found that TGFβ 
regulated SMA expression in TEC via PI3K, Akt, and SMAD3, but not through mTOR (Figure 4-
4B). To determine whether differential expression of SMADs could account for the divergent 
responses to TGFβ2 in NEC versus TEC cultures, we assessed levels of pSMAD2 and 
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pSMAD3 using Western blotting. We found similar basal pSMAD2 and pSMAD3 levels in both 
NEC-B12 and TEC-H8 cultures (Figure 4-S1B and S1C). TGFβ2 further induced SMAD2 and 
SMAD3 phosphorylation in the two cell types to a similar level, with comparable total SMAD2/3 
expression, indicating that TGFβ2-signaling is not altered in TEC-H8 compared to NEC-B12. 
However, TGFβ2-activated SMADs regulate distinct groups of target genes in NEC versus TEC 
suggesting that either additional cofactors are differentially recruited to mesenchymal gene 
promoters in the two cell types or that a different set of mesenchymal genes may be poised for 
transcription in different types of EC.  
Only a fraction of tumor vessels contain SMA+ endothelial cells in vivo  
We observed that primary EC clones displayed a spectrum of SMA expression upon TGFβ2 
stimulation suggesting that not all EC respond identically to TGFβ2 challenge. To test this 
possibility in vivo, we fate-mapped tumor endothelium using Cdh5cre:ZsGreenl/s/l reporter mice to 
indelibly mark all EC (Figure 4-S2A and Figure 4-S2B). Three-dimensional confocal imaging of 
these tumors at high magnification clearly demonstrated that SMA and ZsGreen localized in the 
same cells (Figure 4-S2B, Figure 4-S3, and Movie 4-S1). Consistent with our in vitro findings, 
we observed that in two different orthotopically implanted mammary tumors, only a minor 
fraction (~ 1-10%) of tumor blood vessels contained SMA+ EC, whereas few if any SMA+ EC 
were found in normal mammary glands (Figure 4-4C). On the other hand, blood vessels in 
spontaneous C3-TAg mammary tumors and K-RasG12D lung tumors showed a broad range (0-
25%) of CD31 and SMA co-expression in EC (Figure 4-4D). The higher frequency of 
CD31+/SMA+ EC in these GEMMs could be due to the longer tumor growth period, or in the 
case of lung, be related to underlying plasticity inherent within the vascular bed (i.e. different 
vascular beds show differential proclivity to undergo EndMT). However, it is challenging to 
discriminate between SMA+ pericytes and the closely underlying CD31+ EC using 
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immunostaining in these models and these results must be interpreted with caution; therefore 
the frequency of CD31+/SMA+ EC in these GEMMs could be overestimated.  
These results suggest that EC variably acquire SMA expression in the tumor models we 
evaluated, but SMA+ EC may be more common in other tumor types; for example, in pancreatic 
tumors where fibrosis is a prominent feature and the percentages reported are markedly higher 
(~ 40%) 5. SMA+ EC might appear only transiently during different stages of tumor progression, 
or are generated continuously, but can revert to SMA- EC depending on the balance of EndMT 
promoting (or inhibiting) factors present in the tumor microenvironment. Though 
Cdh5cre:ZsGreenl/s/l mice are a high-fidelity EC lineage tracing model, it is also conceptually 
possible that SMA+ fibroblasts or other mesenchymal-lineage cells may acquire EC markers 
through mesenchymal-endothelial transition (MEndT), which is a reverse process of EndMT. 
While EndMT has been observed in a wide range of conditions, the phenomenon of MEndT in 
tumors is still a matter of debate 28. In contrast to EndMT which may arise spontaneously in 
vitro, generation of EC from lineage-committed mesenchymal cells requires enforced induction 
of multiple EC-selective transcription factors in addition to TGFβ inhibition, indicating that 
MEndT demands restrictive conditions and precise temporal activation of specific regulatory 
factors 29. Therefore, SMA+ EC in our model are more likely to be originated from endothelial-
lineage cells via EndMT rather than mesenchymal-lineage cells through MEndT.  
bFGF opposes the expression of some TGFβ target genes but augments the expression 
of others  
Similar to EMT, we expected that conversion of EC to mesenchymal-like cells was dynamic and 
could be reversed upon removal of TGFβ2 from the culture medium. Indeed, we found that 
when TGFβ2 was removed and cells were returned to their normal growth medium which 
contains bFGF (EC media), SMA expression was rapidly lost and TEC regained their typical EC 
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morphology (Figure 4-S4A and Figure 4-S4B). The same cell population up-regulated SMA 
again after being returned to TGFβ2-containing media, indicating that some TEC may readily 
morph between SMA- endothelial and SMA+ mesenchymal-like phenotypes. We further 
determined that bFGF, but not VEGF, suppressed TGFβ2-induced SMA expression (Figure 4-
5A). Similar to interstitial cells in the heart, bFGF neutralized TGFβ2-stimulated SMA expression 
in TEC at 500 pg/mL, a concentration that was 20-fold lower than the TGFβ2 concentration 
added to the culture medium (Figure 4-5B) 30. Remarkably, acidic FGF (aFGF), the closely 
related isoform of bFGF, did not neutralize SMA expression in TGFβ2-challenged cells at the 
same concentrations. Suppression of TGFβ2-induced SMA expression by bFGF was confirmed 
at the protein level by immunofluorescence (Figure 4-5C). Simply removing bFGF from the 
culture medium promoted TEC to drift towards a mesenchymal-like phenotype indicated by a 
moderate increase in SMA expression, especially in cells maintained at subconfluent conditions 
(Figure 4-S4C). Moreover, these subconfluent cells were highly receptive to TGFβ stimulation 
compared to confluent cultures and showed robust SMA induction and more pronounced 
VEGFR2 suppression (Figure 4-S4C), indicating that loss of cell-cell contact enhances TGFβ 
responses. Thus, bFGF functions both as a potent EC mitogen and a “specification factor” that 
prevents EC drift towards mesenchymal-like cell types, particularly in the presence of TGFβ.  
Next, we carried out a TGFβ2 pathway qPCR array to comprehensively assess the expression 
of 84 TGFβ2 target genes in NEC versus TEC cultures, either with or without addition of bFGF. 
The results showed that, as predicted, TGFβ2 induced distinct expression patterns in NEC 
versus TEC cultures (Figure 4-5D). Furthermore, while bFGF counteracts TGFβ2-induced 
expression of the mesenchymal genes Acta2 and thrombospondin 1 (Thbs1), TGFβ2 and bFGF 
synergistically activate other genes such as Notch1 and S100a8, which were shown previously 
to regulate tumor angiogenesis (Figure 4-5D) 31,32. While repressing SMA, bFGF rescued the 
expression of Vegfr-2, which is suppressed by TGFβ2 challenge; however, bFGF only 
marginally down-regulated expression of the transcription factor Snail, which was previously 
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identified as a master regulator of EndMT (Figure 4-S4D) 33. Interestingly, bFGF expression was 
increased by TGFβ2 stimulation, suggesting a possible autocrine or paracrine feedback loop in 
EC to counteract TGFβ2-induced expression of specific target genes, namely SMA (Figure 4-
S4D). 
To further confirm the protective role of bFGF in neutralizing TGFβ-induced SMA 
expression, we examined gene expression patterns in an additional C3-TAg TEC clone with 
relatively low basal SMA mRNA (TEC-G8). bFGF completely suppressed TGFβ-induced SMA 
expression in TEC-G8, even though the SMA levels were significantly lower than those in the 
SMA+ clone TEC-H8 (Figure 4-S5A and Figure 4-S5B). To assess the interaction between 
bFGF and TGFβ in EC derived from a different tumor model, we isolated lung TEC from K-
RasG12D mouse lung tumors 34. All clones were virtually 100% positive for DiI-Ac-LDL uptake 
and CD31, and strongly expressed VEGFR2 (Figure 4-S6A and Figure 4-S6B). Interestingly, 
unlike C3-TAg TEC clones, the K-Ras TEC clones showed elevated basal SMA protein that was 
detectable by Western blotting even in EC media that contained bFGF, suggestive of a “partial” 
EndMT phenotype in EC subpopulations derived from lung. The expression of SMA and other 
myofibroblast markers including Col1a1, Fn1, and Tagln in these K-Ras clones was further 
stimulated by TGFβ2 in the absence of bFGF, although to a lesser extent when compared to 
SMA+ mammary TEC (Figure 4-S6B and Figure 4-S6C). Addition of bFGF variably antagonized 
the effect of TGFβ on these genes, indicating that bFGF may act through similar pathways in 
different types of EC to maintain EC fate (Figure 4-S6C). Although Twist1 and Twist2 have been 
implicated in the induction of mesenchymal genes during EndMT and EMT; surprisingly, we did 
not observe an up-regulation of Twist1 or Twist2 by TGFβ 35. It is possible that induction of 
these genes in EC requires prolonged stimulation with TGFβ or they play only a marginal role 
during EndMT.  
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Previous studies have demonstrated that bFGF can antagonize TGFβ through the 
MAPK/ERK kinase pathway to suppress fibrogenic effects in epithelial cells and revert EMT, a 
process closely related to EndMT 36. Providing a further link between bFGF and TGFβ signaling, 
basal SMAD2 phosphorylation and TGFβR1 levels are increased when FRS2, an FGFR co-
activator, is depleted using shRNA 37. In lymphatic EC, bFGF was reported to suppress TGFβ-
stimulated SMAD2 activation via MAPK signaling 38. However, we found that although bFGF 
strongly induced EKR1/2 activation, it exerted no observable effects on TGFβ2-stimulated 
SMAD2 phosphorylation and only weakly reduced SMAD3 phosphorylation after a 60-minute 
TGFβ2 stimulation (Figure 4-S7A). Furthermore, inhibition of MAPK/ERK only mildly disabled 
the opposing effect of bFGF on TGFβ-induced SMA (Figure 4-S7B), indicating that bFGF may 
counteract TGFβ signaling through additional mechanisms.  
BMPs, which are members of the TGFβ superfamily, can interact synergistically or 
antagonistically with TGFβ to fine-tune cellular differentiation. For example, BMP-2 controls 
cardiac valve formation through Snail1-mediated EMT during heart development, while BMP-7 
was reported to attenuate TGFβ-induced EndMT in cardiac fibrosis 4,39. In addition, BMP-6 acts 
as a major inhibitor of renal fibrosis as loss of BMP-6 increases SMA and FN1 expression in 
obstructed kidneys 40. However, we found that treatment with BMP-2, 6, or 7 did not overly 
affect SMA or FN1 expression stimulated by TGFβ2 in EC (Figure 4-S7C), suggesting that 
interaction between TGFβ and BMP signaling may be cell-type dependent. More specifically, 
different types of EC may respond differently to combinations of TGFβ and BMP signals. Taken 
together, our results suggest that EndMT, while sharing many features with EMT, is a distinctly 
regulated process that is variably regulated in different vascular beds, or in different disease 
settings.  
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EC challenged with TGFβ secrete their own bFGF which suppresses mesenchymal-like 
differentiation in secondary cultures 
Because bFGF potently blocks TGFβ-stimulated conversion to SMA+ mesenchymal 
cells, and EC up-regulate bFGF in response to TGFβ, we asked whether a cell autonomous 
mechanism in EC could counteract TGFβ challenge. Consistent with our findings, a recent study 
using microarrays also showed that EC challenged with TGFβ up-regulate bFGF mRNA 2. First, 
we confirmed that TGFβ2 dose-dependently increased bFGF mRNA expression, with a 
maximum ~ 10-fold increase after 10 ng/mL TGFβ2 treatment (Figure 4-6A). TGFβ2 also time-
dependently increased bFGF expression, with maximum levels peaking at ~ 10-fold above 
untreated control cells after 48 hours. Next, we harvested the conditioned medium (CM) and 
cellular lysates of TGFβ2-challenged TEC. We found a striking time-dependent increase in 
bFGF secretion and a slight increase in bFGF expression in the cellular lysates after TGFβ2 
stimulation (Figure 4-6B). Notably, we observed that secreted bFGF migrated at three different 
molecular weights, which is consistent with a previous study reporting multiple splice variants of 
bFGF 41.  
To determine whether EC-derived bFGF could oppose TGFβ2 activity, we challenged 
TEC cultures with TGFβ2 and then harvested the CM to re-challenge secondary cultures 
(Figure 4-6C, a). We found that CM collected from TEC stimulated with TGFβ2 induced ~ two-
fold less SMA expression in secondary cultures treated with cell-free media containing equal 
amounts of TGFβ2 (Figure 4-6C, b-c). The decrease in SMA expression in secondary cultures 
correlated with the presence of secreted bFGF protein in the CM. qPCR analysis of additional 
mesenchymal and EC genes, including Tagln, Pdgfa, Thbsp1, Cd31, and Cdh5, further showed 
that the CM of TGFβ2-challenged primary cultures could oppose the effects of TGFβ2 in 
secondary cultures. In contrast, S1008a, which can be induced synergistically by TGFβ2 and 
bFGF as revealed by the TGFβ-pathway array (refer to Figure 4-5D), showed a similar 
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expression pattern after the CM treatment, while the expression of Snail was not affected. To 
test if the TGFβ2-antagonizing effect of the CM was due specifically to an increased bFGF 
production by TEC, we used a bFGF blocking antibody (BA) and an FGFR kinase inhibitor (KI) 
to neutralize bFGF activity. As expected, blocking bFGF signaling by either compound 
increased TGFβ2-stimulated SMA mRNA expression in TEC (Figure 6C, d). However, 
neutralizing bFGF with a BA or KI only had a modest effect on SMA expression, possibly 
because SMA mRNA levels were already maximized by the addition of TGFβ2. 
Our results have shown that EC exhibit heterogeneity in their responses to TGFβ: some 
express high basal SMA and react to TGFβ by generating SMA+ myofibroblast-like cells with 
distinct functions, whereas others have low basal SMA and transition to SMA- fibroblast-like 
cells (Figure 4-7). These results are remarkably similar to what has been reported for epithelial 
cells and suggests parallels between the processes of EMT and EndMT 42. However, EC which 
have undergone a partial mesenchymal-like transition may be directed to a stable SMA+ 
mesenchymal-like phenotype perhaps after prolonged TGFβ stimulation or disruption in bFGF 
signaling 37. In addition to regulation by growth factors and cytokines, EndMT may also be 
controlled by epigenetic barriers within the different subpopulations of EC that guides them 
towards one lineage or the other. These epigenetic restrictions could explain heterogeneity in 
EC responses to TGFβ signaling. EC markedly increase bFGF production in response to 
stimulation by TGFβ2; thus, one EC that receives TGFβ could protect neighboring EC from 
mesenchymal-like differentiation through a lateral inhibitory mechanism involving bFGF 
secretion 43. A similar mechanism of lateral inhibition involving VEGF/Notch signaling is well 
known in EC, as it occurs during fate determination of tip cells during sprouting angiogenesis 44. 
In tumors, organ fibrosis, and other chronic inflammatory conditions, the extent of EndMT will 
likely be determined by local concentrations of several interacting cytokines and growth factors, 
including TGFβ, bFGF, and BMPs, and perhaps on organ-specific properties and heterogeneity 
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of the EC that form the microvasculature 45. Notably, in endoglin- (a TGFβ2 co-receptor) 
deficient mice, EndMT in tumor vessels was exacerbated and the frequency of metastases was 
increased 13. On the other hand, endoglin deficiency delayed resistance to an anti-angiogenic 
therapy targeting VEGF. These findings bring to light the importance of further understanding 
the molecular mechanisms that promote and inhibit EndMT in tumors and in other pathological 
conditions.  
Experimental Procedures 
EC isolation, cell culture and media 
Mammary NEC and TEC were isolated from C3-TAg (FVB/N C31-TAg) mice and FVB 
wild-type mice, respectively 21. We previously isolated prostate TEC from TRAMP mice 8, and K-
Ras lung TEC were isolated from K-RasG12D mouse lung tumors 34. Fluorescently labeled 
acetylated low-density lipoprotein (DiI-Ac-LDL) (Biomedical Technologies) were incubated with 
lung TEC clones to examine cell purity under a fluorescent microscope 46. EC clones were 
maintained in 1 g/L d-glucose DMEM (LG-DMEM, Gibco) supplemented with 10% fetal bovine 
serum (FBS), 10% Nu-Serum IV (BD), 5 ng/mL bFGF (Peprotech), 10 ng/mL vascular 
endothelial growth factor A (VEGF) (Peprotech), and 20 USP units/mL heparin (Sigma). Mouse 
mesenchymal stem cells (MSC) were purchased from Gibco and were maintained in DMEM/F-
12 (Gibco) with 10% MSC-qualified FBS (Gibco). All media were supplemented with antibiotic–
antimycotic (Gibco). 
Unless otherwise stated, 5 ng/mL bFGF and/or 10 ng/mL TGFβ2 in 20% FBS or 1% FBS 
LG-DMEM was used to treat cells for 48 hours prior to protein or RNA extraction. BMP-2 
(Peprotech), BMP-6 (Peprotech), and BMP-7 (Peprotech) were used at 100 ng/mL. Small-
molecule inhibitors were added to the media for one hour before TGFβ2 treatment. Reagents 
used: TGFβ2R inhibitor (SB431542, Sigma), phosphoinositide 3-kinase (PI3K) inhibitor 
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LY294002 (Sigma), Akt inhibitor VIII (EMD Millipore), Smad3 inhibitor SIS3 (Calbiochem), 
mammalian target of rapamycin (mTOR) inhibitor rapamycin (Sigma), MEK (MAPK/ERK kinase) 
1/2 inhibitor U0126 (Calbiochem), bFGF neutralizing antibody (Millipore, 05-117), and FGF 
receptor (FGFR) kinase inhibitor (Calbiochem). 
Real-time quantitative PCR (qPCR) 
Total RNA isolation was completed using an RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions, and cDNA synthesis was carried out using an iScript cDNA 
Synthesis Kit (Bio-Rad). qPCR was run in triplicate in 10 µL/reaction with 2X Maxima SYBR 
Green (ThermoFisher) on an Applied Biosystems Step One Plus analyzer. The threshold cycle 
(Ct) values were determined by Step One Software 2.2.2 by Applied Biosystems. Ct values of 
Gapdh gene expression were used as an endogenous control. The relative expression of each 
gene was quantified using the formula: 2e(Ct of Gapdh – Ct of gene X) = fold increase of reference gene 
expression. Primer sequences are listed in Table 4-S1. Heat maps were generated using Gene-
E (http://www.broadinstitute.org/cancer/software/GENE-E/.)  
Western blots 
Cells were lysed in RIPA buffer complemented with phosphatase and protease inhibitor 
cocktails (Sigma) for protein extraction. Protein concentrations were determined by Bradford 
assays, and ~ 30 µg per sample was used for Western blotting. For non-phosphorylated protein 
detection, membranes were blocked and antibodies were added in 5% milk tris-buffered saline 
with 0.1% Tween 20 (TBST), and for phosphorylated protein detection, 5% bovine serum 
albumin (BSA) TBST was used. Membranes were incubated with primary antibodies at 4 °C 
overnight and then with secondary antibody at room temperature for one hour. Primary 
antibodies: 1:1000 mouse anti-SMA (Sigma, A5228), 1:1000 rabbit anti-phospho-Ser 465/467 
SMAD2 (pSMAD2) (Cell Signaling, 3108), 1:1000 rabbit anti-phospho-Ser 423/425 SMAD3 
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(pSMAD3) (Millipore, 0713-89), 1:1000 rabbit anti-SMAD2 (Cell Signaling, 5339), 1:1000 rabbit 
anti-SMAD2/3 (Cell Signaling, 8685), 1:1000 rabbit anti-fibronectin (Abcam, ab2413), 1:1000 
rabbit anti-bFGF (Sigma), 1:1000 rabbit anti-phospho-Thr 202/204 ERK (pERK) 1/2 (Cell 
Signaling, 4370), 1:2000 rabbit anti-ERK1/2 (Cell Signaling, 9102), 1:1000 rabbit anti-VEGF 
receptor 2 (VEGFR2) (Cell Signaling, 55B11), and 1:2500 rabbit anti-GAPDH (Cell Signaling, 
5174). Secondary HRP-conjugated antibodies: 1:10,000 horse anti-mouse and 1:10,000 goat 
anti-rabbit antibodies (Vector Laboratories). 
Wound closure scratch assay and live imaging 
Cells were plated at 1.0 X 105 cells/well in 6-well plates. Twenty-four hours later, the 
monolayer was gently scratched with a 200 µL pipette tip across the center of the well. An 
Olympus IX70 Inverted Live Cell System was used for time-lapse imaging of the cells at a 
minimum of four locations/well at 20-minute intervals until the scratch wound was completely 
closed. The images were acquired with the Volocity 6.2 software package (Perkin Elmer) and 
analyzed using TScratch software (available at: http://www.cse-lab.ethz.ch) according to the 
developers’ instructions. 47. The open areas on the images were quantified with the software’s 
automated image analysis and expressed as relative area closure with an arbitrary area unit 
assigned by the software. Phase contrast images were captured with a Hamamatsu ORCAR2 
camera. 
Matrigel tube formation assay 
Growth factor-reduced Matrigel (Corning, 356230) was first plated into 96-well plates 
and allowed to set for 30 minutes at 37°C. Cells were pre-incubated in 10% FBS medium with or 
without TGFβ2 for 16 hours before being detached and plated in 10% FBS medium with or 
without TGFβ2 in Matrigel-containing wells in triplicate at a density of 1.0 X 104 cells/well. Phase 
contrast images (4X) were taken on an Evos® XL Core Cell Imaging System (Life Technologies) 
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at ~ seven hours. Images were processed with ImageJ using the “find edges” feature to 
enhance the contrast. Quantification was done by counting vessel-like cords that were formed 
by at least two non-adjacent cells. A 3 X 3 grid was superimposed on each image, and at least 
four random squares were counted per image to obtain an average number of tubes per image.   
Flow cytometry 
Flow cytometry was performed using a BD Accuri® C6 Flow Cytometer as previously 
described with data analyzed post-hoc using FloJo (version X) 21. Antibodies: PE rat anti-mouse 
CD31 (BD Pharmingen, 553373), PE rat anti-mouse CDH5 (VE-cadherin) (BD Pharmingen, 
562243), and rat anti-mouse IgG (BD Pharmingen, 55393) at a ratio of 1.5 µL antibody to 100 
µL of cell suspension. 
Tumor studies in mice  
C3-TAg mice were provided by the Mouse Phase 1 Unit from the Lineberger 
Comprehensive Cancer Center at UNC Chapel Hill. Tumors were harvested when mice were 
approximately five months of age. Cdh5cre:ZsGreenl/s/l mice were generated by crossing R26 
ZsGreen mice (Jackson Laboratory, 007906) and Cdh5-Cre mice (Jackson Laboratory, 
006137). E0771 murine mammary tumor cells (CH3 BioSystems, 940001) or PyVMT tumor cells 
isolated from the PyVMT mice were suspended in Matrigel (Corning, 356234) at a density of 1.0 
X 107 cells/mL, and 100 µL of cell suspension was orthotopically injected into the mammary fat 
pats of seven week-old female Cdh5cre:ZsGreenl/s/l mice 48. Tumors were harvested when they 
reached 1 cm3 in size, and normal mammary glands from age-matched littermates were 
harvested at the same time. Lung tumors were obtained from K-RasG12D mice 34. Tissues were 
fixed in 4% paraformaldehyde and cryoprotected in 30% sucrose-phosphate buffered saline 
(PBS) before OCT embedment and cryosection. All mouse experiments were carried out under 
approval of the Institutional Animal Care and Use Committee at UNC-Chapel Hill. 
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Immunofluorescence (IF) 
IF methods were described previously 8. Antibodies used were: 1:100 rat anti-mouse 
CD31 antibody (BD, 550274), 1:200 Alexa Fluor® 488 goat anti-rat antibody (Invitrogen, 
A11006), and 1:500 monoclonal mouse anti-α-SMA Cy3 antibody (Sigma, C6198). Slides were 
mounted with Vectashield Hardset Mounting Medium with DAPI (Vector Labs) and imaged on a 
Zeiss CLSM 710 or 700 Spectral Confocal Laser Scanning Microscope. 
Three-dimensional confocal microscopy 
Sections were stained as described above, and imaged on a Zeiss CLSM 710 Spectral 
Confocal Laser Scanning Microscope using cubic voxels to capture the z-dimension. Three-
dimensional projections, orthogonal slices, and the supplementary movie (Movie 4-S1) were 
generated using ImageJ (http://imagej.nih.gov/ij/). 
TGFβ pathway qPCR array 
The array was carried out in duplicate using the Mouse TGFβ Signaling Targets 
RT² Profiler™ PCR Array (SA Biosciences, PAMM-235Z) according to the manufacturers’ 
instructions. Cells were plated and exposed to TGFβ2 and/or bFGF for 48 hours. Total RNA 
was purified with an RNeasy Mini Kit (Qiagen) and cDNA synthesis was performed with an 
iScript cDNA Synthesis Kit (Bio-Rad). ABI 7900HT Quantitative PCR System was used for the 
qPCR array and the data were analyzed with SA Biosciences’ RT² Profiler™ PCR Array Data 
Analysis Online Software.  
Conditioned-media (CM) treatment of TEC-H8 
CM collected from TEC-H8 treated with or without TGFβ2 (10 ng/mL) for 48 hours were 
concentrated using Amicon Ultra-15 Centrifugal Filter Unit (Millipore) or Pierce Protein 
Concentrators (Thermo Scientific). For Western analysis of bFGF, 25 µL of the concentrated 
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CM was used, and the remaining concentrated CM were then divided equally to treat a new 
batch of TEC-H8 for 48 hours in the presence or absence of freshly added TGFβ2. Cell lysates 
were collected for Western and qPCR analyses.  
Statistics 
All values are expressed as ± standard error of mean (SEM). Results were analyzed by 
a student’s t-test or ANOVA using GraphPad Prism 5 software. P values less than 0.05 were 
considered significant.  
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Figures 	
 
 
Figure 4-1. Characterization of NEC and TEC clones.  
(A) Representative CD31 and CDH5 FACS histogram plots of NEC and TEC clones. Open 
curves represent cells stained with CD31 or CDH5 antibodies, and solid curves indicate FACS 
histogram plots of cells stained with an isotype-matched control antibody. (B) Relative mRNA 
expression by qPCR of Acta2 (SMA), Cd31, and Vegfr-2 in NEC and TEC clones. Gapdh was 
used as an endogenous control and relative mRNA expression of each gene was expressed as 
fold increase compared to NEC. MSC were used as a positive control. 
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Figure 4-2. Subpopulations of EC undergo a spectrum of EndMT in response to TGFβ2 
stimulation.  
(A) Western blots showing that TGFβ increases SMA protein expression in TEC-H8, a clone 
that has high basal SMA mRNA levels. Three clones representing NEC (NEC-B12), SMA-low 
TEC (TEC-A2), and SMA-high TEC (TEC-H8) were treated with 10 ng/mL TGFβ2 in growth 
factor (GF)-reduced media (20% FBS LG-DMEM) for 48 hours before being subjected to 
Western blotting. MSC were used as a positive control. (B) Western blots showing SMA 
expression in NEC-B12 and TEC-H8 after stimulation with 10 ng/mL TGFβ1, TGFβ2, or TGFβ3 
for 48 hours. (C) Western blots showing SMA expression in TEC-D8 and prostate TEC isolated 
from TRAMP mice after stimulation with 10 ng/mL TGFβ2 for 48 hours. (D) Immunofluorescence 
images of TEC-H8 stimulated with 10 ng/mL TGFβ2 for 48 hours. Cells were stained with SMA 
(red, a), CD31 (green, b), and DAPI (blue) as shown in the merged image (c). (d) Merged 
confocal image of TGFβ2-stimulated TEC-H8. The white arrowheads indicate co-localization of 
SMA (red) and CD31 (green) in the same cell. Scale bars = 50 µm. 
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Figure 4-3. SMA+ TEC are functionally different from NEC. 
(A) (a) Wound closure rates of NEC-B12 and TEC-H8 treated with or without TGFβ2. (b) 
Representative images of the wound closure at indicated time points. White dotted lines indicate 
the migration fronts of cells. Cells were exposed to 10 ng/mL TGFβ2 in 20% FBS LG-DMEM for 
~ 30 minutes before imaging (n = 3). Scale bar = 100 µm. Statistical significance was 
determined by two-way ANOVA (**P < 0.001). (B) Representative phase-contrast images of 
Matrigel tube formation of NEC (a, b), TEC-G8 (c, d), and TEC-H8 (e, f) with or without TGFβ2 
treatment. (g) Quantification of tubes by counting the number of tubes per field. Scale bar = 1 
mm. n = 3-4 observations. Statistical significance was determined using a Student’s t test (*P < 
0.05).  
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Figure 4-4. Only a fraction of tumor vessels contain SMA+ TEC.  
(A) Heat-map representation of mesenchymal and endothelial marker mRNA levels by qPCR in 
NEC-B12 and TEC-H8 clones treated with or without of TGFβ2. Gapdh was used as an 
endogenous control. The heat map was generated using Gene-E software. (B) Western blots 
demonstrating that TGFβ2 up-regulates SMA expression in TEC-H8 via SMAD2/3 and PI3K 
pathways. TGFβ2R inhibitor (SB431542): 10 µM, PI3K inhibitor (LY294002): 3 µM, Akt inhibitor 
VIII: 5 µM, SMAD 3 inhibitor (SIS3): 3 µM, and mTOR inhibitor (rapamycin): 100 nM. (C) 
Representative immunofluorescent images of normal mammary glands (Normal MG) (a-c) and 
mammary tumors (d-f) from lineage-traced Cdh5cre:ZsGreenl/s/l mice showing SMA staining 
(red), blood vessels that are tagged with ZsGreen (green), and nuclear staining with DAPI 
(blue). Mammary tumors were induced by orthotopic injection of E0771 or PyVMT tumor cells in 
Cdh5cre:ZsGreenl/s/l mice. The arrowheads indicate ZsGreen+/SMA+ vessels and asterisks 
indicate ZsGreen+/SMA- vessels. (g) Quantification of vessels containing ZsGreen+/SMA+ cells 
in normal mammary glands and mammary tumors. (D) Representative immunofluorescent 
staining of SMA (red), CD31 (green), and DAPI (blue) in spontaneous C3-TAg mammary tumors 
(a-c) and K-RasG12D lung tumors (d-f). The arrowheads indicate ZsGreen+/SMA+ vessels. 
Scale bars = 100 µm. (g) Frequency distribution of vessels containing CD31+/SMA+ cells in C3-
TAg and K-RasG12D tumors. Each bar represents one microscopic field of view. 
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Figure 4-5. bFGF opposes the expression of some TGFβ target genes but augments the 
expression of others.  
(A) Western blots showing that bFGF but not VEGF blocks SMA protein expression in TEC-H8. 
(B) (a) Representative Western blots demonstrating that bFGF suppresses TGFβ2-induced 
SMA expression in a dose-dependent manner. (b) Densitometry quantification of SMA 
expression (n = 3). Statistical significance was determined using One-way ANOVA with 
Bonferroni post test (**P < 0.01). ADU: arbitrary density units. (c) Western blots showing that 
aFGF does not suppress TGFβ2-induced SMA expression. (C) Representative 
immunofluorescent images of SMA expression in TEC-H8 stimulated with TGFβ2 in the 
absence (a) or presence (b) of bFGF. (c) Quantification of SMA+ cells from 
immunofluorescence. Scale bar = 100 µm. (D) Heat map and hierarchical clustering of gene 
expression of NEC and TEC-H8 clones analyzed using the Mouse TGFβ Signaling Targets 
RT² Profiler™ PCR Array. Cells were stimulated for 48 hours with TGFβ2 and/or bFGF as 
indicated, and the arrays were performed in duplicate. Results were normalized and log-
transformed, and genes were clustered using Pearson’s correlation.  
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Figure 4-6. EC challenged with TGFβ secrete their own bFGF which suppresses 
mesenchymal-like differentiation in secondary cultures. 
(A) Dose- and time-dependent induction of bFGF mRNA expression in TEC-H8 challenged with 
TGFβ2. In the dose-response experiment, cells were treated with increasing concentrations of 
TGFβ2 for 48 hours, and in the time-dependent experiment, cells were stimulated with 10 ng/mL 
TGFβ2. (B) Western blots showing secreted and intracellular bFGF in TEC-H8 challenged with 
10 ng/mL TGFβ2 for the indicated times. Ponceau staining (PS) and GAPDH were used as 
loading controls for secreted proteins and cell lysates, respectively. The arrowheads indicate 
bFGF isoforms of different molecular weights. (C) Secondary TEC-H8 culture treatments with 
conditioned media (CM) obtained from TEC-H8 challenged with TGFβ2. (a) Schematic diagram 
of the CM experiment. Media conditioned by TEC-H8 stimulated with or without TGFβ2, and 
media containing only TGFβ2 were concentrated and used to treat secondary TEC-H8 cultures 
for 48 hours. (b) Western blot of SMA expression in the secondary TEC cultures treated with 
CM or cell-free media, and Western analysis of secreted bFGF in the CM and cell-free media. 
(c) qPCR analysis of changes in mRNA expression in secondary TEC-H8 cultures treated with 
CM or cell-free media. (d) qPCR analysis of Acta2 (SMA) mRNA expression in TEC-H8 treated 
with increasing doses of either a bFGF blocking antibody (BA) or a FGFR kinase inhibitor (KI) in 
the presence of 10 ng/mL TGFβ2 for 48 hours. From left to right: the bFGF BA concentrations 
are 0 µg/mL, 20 µg/mL, 0 µg/mL, 10 µg/mL, 15 µg/mL, and 20 µg/mL, and the FGFR KI 
concentrations are 0 nM, 200 nM, 0 nM, 40 nM, 120 nM, and 200 nM. Graphs are 
representative of three independent experiments. Error bars represent SEM (n = 3). 
Significance was determined using a one-way ANOVA and is indicated by an asterisk (P < 
0.05).  
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Figure 4-7. Schematic diagram of TGFβ and bFGF interactions during EndMT.  
Heterogeneous EC populations consist of cells with a spectrum of basal SMA mRNA expression 
suggesting that some EC possess intrinsic ability to gain SMA protein expression. Transient 
TGFβ exposure stimulates EC to undergo reversible EndMT where some EC transition into 
SMA+ intermediate cells whereas others form SMA- intermediate cells. EC also up-regulate 
bFGF in response to TGFβ, providing a mechanism to counteract TGFβ, thereby maintaining 
endothelial specification via an autocrine or paracrine loop. Prolonged TGFβ stimulation may 
force EC to reach a “point of no return” and enter an irreversible or stable EndMT state. EC at 
this stage may completely lose endothelial specification, which cannot be rescued by bFGF 
addition or TGFβ removal, and generate either SMA+ or SMA- mesenchymal-like cells. It is also 
possible there are epigenetic barriers are in place among heterogeneous EC that restricts SMA- 
mesenchymal-like EC from becoming SMA+, but these barriers could be overcome depending 
on specific conditions in the tumor microenvironment. 
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Figure 4-S1. Characterization of FN1 expression and SMAD2/SMAD3 phosphorylation in 
NEC versus TEC challenged with TGFβ2.  
(A) Western blots of fibronectin 1 (FN1) expression in NEC-B12 and TEC-H8 after stimulation 
with 10 ng/mL TGFβ2 for 24 and 48 hours. (B) Western analysis of pSMAD2 (Ser 465/467) in 
NEC-B12 and TEC-H8 clones stimulated with 10ng/mL TGFβ2 for indicated time points. (C) 
Western analysis of pSMAD3 (Ser 423/425) in NEC-B12 and TEC-H8 clones stimulated with 
10ng/mL TGFβ2 for indicated time points. 
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Figure 4-S2. Generation of the Cdh5cre:ZsGreenl/s/l lineage-tracing reporter mice.  
(A) (a) A mouse carrying an endothelial-specific Cre-recombinase driven by the Cdh5-promoter 
was crossed with a reporter mouse that carries a ZsGreen fluorescent protein gene downstream 
of a floxed-stop codon and a CAG promoter. Cre-excision of the stop codon allows for 
expression of ZsGreen in all EC of the compound mice (Cdh5cre:ZsGreenl/s/l). (b) Diagram 
depicting the injection of mammary tumor cells orthotopically into the mammary glands of 
Cdh5cre:ZsGreenl/s/l mice to induce mammary tumors. (B) Confocal images of the vasculature of 
normal mammary tissue of Cdh5cre:ZsGreenl/s/l mice showing a two-dimensional (2D) single 
focal plane image (a) and a compressed three-dimensional volume image of multiple focal 
planes (b). Scale bar = 50 µm. (C) E0771 mammary tumors orthotopically induced in the 
Cdh5cre:ZsGreenl/s/l mice were stained for SMA (red) and DAPI (blue). ZsGreen (green) is an 
endogenous fluorophore that acts as a proxy for endothelium. Square images: projections of a 
confocal Z-stack image of 10.3 µm; flanking rectangles: orthogonal sections of the merged 
image. The white arrowheads indicate the cells positive for both SMA and ZsGreen. The black 
arrowheads indicate colocalization in the z-plane. Scale bar = 10 µm.  
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Figure 4-S3. Representative tile immunofluorescent images of mammary tumors from 
Cdh5cre:ZsGreenl/s/l mice.   
(A) E0771 mammary tumors orthotopically induced in the Cdh5cre:ZsGreenl/s/l mice were stained 
for SMA (red) and DAPI (blue), ZsGreen (green) labels the endothelium. Scale bar = 10 µm. (B) 
Enlarged images of Regions 1, 2, and 3 in (A). Asterisks indicate cells positive for both ZsGreen 
(green) and SMA (red). Scale bar = 5 µm. 
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Figure 4-S4. bFGF reverses TGFβ2-induced morphological changes and target gene 
expression in SMA+ TEC.  
(A) Western analysis showing that SMA expression in TEC-H8 can be turned on and off 
depending on the culture medium. SMA expression was up-regulated in the presence of TGFβ2 
(48-hour treatment), and was suppressed by EC media which contains bFGF. The same cell 
population re-expressed SMA when returned to media containing TGFβ2 but not bFGF. (B) 
Phase-contrast images of TEC-H8 showing that EC morphology was maintained by media 
containing bFGF. The same cell population was cultured in EC media, transferred to media 
containing TGFβ2 for two days, and then returned to EC media. (C) Western blots of SMA 
expression in TEC-H8 when bFGF was removed from the medium for the indicated days. (D) 
qPCR analysis of gene expression in TEC-H8 treated with TGFβ2, bFGF, or a combination of 
both.  
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Figure 4-S5. bFGF suppresses TGFβ2-induced SMA expression in multiple EC clones.  
(A) qPCR analysis of SMA expression in mammary NEC, SMA-low TEC (clone G8) and SMA-
high TEC (clone H8) in response to TGFβ2 treatment with or without bFGF. The SMA 
expression patterns remained unchanged even after multiple passages (>5) in culture as 
indicated by graphs from two different experiments (Exp. 1 and Exp. 2). (B) SMA expression at 
protein levels in the same clones as (A) shows a similar trend after incubation with TGFβ2 with 
or without bFGF. Note although that SMA induction by TGFβ2 was weaker in NEC-B12 and 
TEC-G8, addition of bFGF completely blocked the effect of TGFβ2.  
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Figure 4-S6. bFGF suppresses TGFβ2-induced mesenchymal gene expression in K-Ras 
lung TEC clones.  
(A) Characterization of K-Ras lung TEC isolated from K-RasG12D mouse lung tumors. (a) 
Phase contrast image of isolated K-Ras lung TEC. (b) Fluorescent image of the isolated K-Ras 
lung TEC in (a) labeled with DiI-Ac-LDL (red). (c) Representative CD31 FACS histogram plots of 
NEC and TEC clones showing that all clones are CD31+. Solid curves represent cells stained 
with isotype-matched control antibody, and open curves indicate FACS histogram plots of cells 
stained with CD31 antibodies. (B) TGFβ2 suppresses VEGFR2 expression and increases SMA 
expression in K-Ras lung TEC by Western blotting. (C) Gene expression in K-Ras lung TEC by 
qPCR after TGFβ2 stimulation with or without bFGF.  
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Figure 4-S7. bFGF weakly blocks TGFβ2-induced SMA expression through ERK/MAPK 
signaling and inhibition of SMAD3 phosphorylation.  
(A) Western blots showing TGFβ2-induced pSMAD2 and pSMAD3 levels in TEC-H8 also 
challenged with bFGF. Cells were pre-incubated with 5 ng/mL bFGF for 90 minutes before 10 
ng/mL TGFβ2 addition for a further 60 minutes. (B) Western analysis of SMA expression in 
TEC-H8 stimulated with TGFβ2 and bFGF in the presence or absence of 10 µM MEK inhibitor 
U0126 for 48 hours. (C) Western analysis of FN1 and SMA expression in TEC-H8 stimulated 
with 10 ng/mL TGFβ2, with or without 100 ng/mL BMP-2, 100 ng/mL BMP-6, or 100 ng/mL 
BMP-7 for 48 hours.  
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Movie 4-S1. Three-dimensional projection of confocal z-stack immunofluorescent images 
of SMA+/ZsGreen+ cells in Cdh5cre:ZsGreenl/s/l mouse mammary tumors.  
Orthotopic E0771 tumors from the Cdh5cre:ZsGreenl/s/l mice with vessels endogenously labeled 
with ZsGreen (green) were immunostained with SMA (red).  
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Table 
Table 4-S1. Primer list. 
 
Genes Assession number Forward Reverse 
Acta2 NM_007392.2 
TCCAGCTATGTGTGAAGAGGAA
G 
CAACCATTACTCCCTGATGTC
TG 
Cd31 NM_001032378.1 AAGCCAACAGCCATTACGGT AGCCTTCCGTTCTCTTGGTG 
Cdh5 NM_009868.4 GTTTGCCCTGAAGAACGAGG CTGCCCATACTTGACCGTGA 
Cdh11 NM_009866.4 GTCAACGACAACCCACCAAAG 
GCCTTCACCCTTCCTACTTCC
T 
Cnn1 NM_009922.4 TGGAACACTGCGACACACTCA GCGAGGAAGCCCATACACTG 
Des NM_010043.1 CCTTCTCTGCTCTCAACTTCCG 
GTAGCCTCGCTGACAACCTC
TC 
Eng NM_001146348.1 TGTTCCTGGTCCTCGTTTCG 
TTGACTCTTGGCTGTCCTTG
G 
Fn1 NM_010233.1  TGGCTGAAGTCGCAAGGAA 
TGTAGGTGAACGGGAGGACA
C 
Gapdh NM_008084.2 CAGCCTCGTCCCGTAGACAA CAATCTCCACTTTGCCACTGC 
Pdgfa NM_008808.3 GCCAAAGTGGAGTATGTCAGGA CGATGGTCTGGGTTCAGGTT 
Pdgfrb NM_001146268.1 GTTCTGGGACGCACTCTTGG 
TCTCGCTACTTCTGGCTGTC
G 
S1008a NM_013650.2 GAGTTCCTTGCGATGGTGATAA CTCCTTGTGGCTGTCTTTGTG 
Snail NM_011427.2 ACCCACTCGGATGTGAAGAGA 
GAGGTAGCAGGGTCAGCGA
G 
Tagln NM_011526.5 GACTCTAATGGCTTTGGGCAG TATGCTCCTGGGCTTTCTTCA 
Tgbr2 NM_009371.3 CCATCTGTGAGAAGCCGCAT 
GTGAAGCCGTGGTAGGTGAG
C 
Thbs1 NM_011580.3 AATGTGGTGCGTGTCCTCCT 
GATTGAAGCAAGCATCAGGC
A 
Thbs2 NM_011581.3 CAATGACGGTGTGAGCGATG CCTCGCCATTGTTGTCTGTG 
Tnc NM_011607.3 GCAACCCTGCCAAAGAGACC TGTGAGACACGGCGGAGATT 
Vegfr-2 NM_010612.2 TGTGACCAAGAGTGACCAAGG GGCTTTGTGTGAACTCGGAC 
Vim NM_011701.4 GAGAGAGGAAGCCGAAAGCAC TCCACTTTCCGTTCAAGGTCA 
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CHAPTER 5: Conclusions and Future Directions 
Conclusions 
In this thesis project, we have described a highly efficient EC isolation method based on 
an antibody-facilitated column sorting and cloning-ring capture of EC colonies, with which we 
have been able to consistently obtain highly pure EC clones from both tumors and normal 
tissues. Characterization of these clones shows that the tumor endothelium has distinct gene 
expression profiles that are different from those of the normal endothelium. Our studies have 
further demonstrated that TEC are heterogeneous: some EC are mesenchymal-like and may 
possess intrinsic ability to transdifferentiate into SMA+ myofibroblast-like cells in response to 
TGFβ (termed as “TGFβ responder EC” hereafter), whereas others do not up-regulate SMA 
when challenged with TGFβ (termed as “TGFβ non-responder EC” hereafter). These different 
EC types respond to TGFβ differently even though the downstream SMAD2/3 signaling 
pathways are similarly activated, suggesting that TGFβ-regulated gene expression may be 
dictated by different epigenetic landscapes in these cells.  
In addition, we have discovered that a mitogen, bFGF, is crucial in maintaining the 
endothelial identity in the face of TGFβ challenge. bFGF suppresses mesenchymal gene 
expression stimulated by TGFβ, and up-regulates endothelial markers such as VEGFR2, 
essentially reversing EndMT instigated by TGFβ. This antagonistic effect on TGFβ signaling is 
highly specific to bFGF, but not other growth factors including VEGF and aFGF at a similar 
concentration. Surprisingly, EC also secrete bFGF in response to TGFβ, perhaps to counteract 
TGFβ-stimulated differentiation. In fact, conditioned media taken from TGFβ-treated EC are 
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able to suppress mesenchymal gene expression in a different batch of EC exposed to TGFβ, 
suggesting that the endothelium may be equipped with an autocrine or paracrine protective 
mechanism to preserve their endothelial identity.  
Together, our work has discovered that the tumor endothelium is comprised of polarized 
cell populations that differentially respond to the EndMT inducer, TGFβ. bFGF signaling potently 
suppresses TGFβ-regulated EndMT, and is also up-regulated in TGFβ-stimulated EC. 
Understanding the regulatory pathways that control the myofibroblast generation from these 
different EC subtypes may facilitate the development of druggable targets to inhibit 
myofibroblast activation in both tumors and other pathological conditions.  
Future Directions 
1. What are the molecular mechanisms that dictate the differences between TGFβ 
responder EC and TGFβ non-responder EC? 
TGFβ responder and non-responder EC have distinct gene expression patterns that are 
almost completely opposite of each other (Figures 4-2D and 4-3A). However, it is not known if 
the TGFβ responders are an altered population derived from the non-responder EC during the 
course of disease development, or they are preexisting cells in the normal endothelium but are 
enriched by the dysregulated microenvironment in tumors. It also remains unclear if these two 
EC subpopulations are inter-convertible.  
Stable acquisition of mesenchymal features requires epigenetic alterations that are 
inheritable over multiple cell divisions 1. It is therefore possible that the TGFβ responsiveness of 
these two EC types is determined by their unique epigenetic conformations. Methylation at the 
5-position of cytosine (5mC) in CpG dinucleotides carried out by DNA methytransferases 
(DNMTs) represents a major epigenetic regulation mechanism. Studies by other laboratories 
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have highlighted the importance of DNMTs in myofibroblast conversion. For instance, in gastric 
tumors, tumor-promoting CAF have wide-spread loss of DNA methylation 2, and the DNMT 
inhibitor 5-Azacytidine (5-Aza) promotes myofibroblast differentiation from MSC 3.  
To determine if DNMTs are also important in maintaining endothelial identity, we used a 
small molecule inhibitor of DNMTs, 5-Aza, to treat non-responder EC. Pre-incubation with 5-Aza 
markedly potentiated TGFβ-induced myofibroblast gene SMA expression at protein levels in all 
four non-responder clones examined (Figure 5-1A), which was confirmed by 
immunofluorescence staining (Figure 5-1B). Other mesenchymal genes, including Col1a1 and 
Tagln, also showed a similar trend (Figure 5-1C).  
Three classes of DNMTs have been described in mammalian cells: DNMT1, DNMT2, 
and the DNMT3 members which includes DNMT3a, DNMT3b, and DNMT3L. DNMT2, also 
termed TRDMT1, methylates tRNA, and DNMT3L is catalytically inactive, although it may play a 
role in transcriptional repression 4,5. The most abundant DNMT isoform in mammalian somatic 
cells is DNMT1, which is responsible for copying and maintaining the CpG site methylation 
status from the parental to the daughter DNA strand during cell division. DNMT3a and DNMT3b, 
however, are less involved in methylation pattern maintenance due to their inability to 
distinguish unmethylated CpG sites from hemi-methylated ones, but they are considered to be 
important in de novo methylation during development 6. 
To establish which DNMT isoform is responsible in the regulation of myofibroblast genes 
in EC, we used siRNA to deplete Dnmt1, Dnmt3a, and Dnmt3b individually. Knocking down of 
Dnmt1 mirrored the effect of 5-Aza in TGFβ non-responders (Figure 5-2), whereas silencing of 
the other two Dnmt isoforms did not (Figure 5-2B). Other genes such as Fn1 and Vegfr2 were 
not affected by Dnmt1 depletion (Figure 5-2B), suggesting the effect of DNMT inhibition is highly 
specific to a subset of mesenchymal genes. Moreover, pulse treatment of these non-responders 
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with 5-Aza led to an irreversible change of morphology from EC’s typical cobblestone 
appearance to a spindly mesenchymal phenotype (Figure 5-3A). Transient incubation with 5-
Aza also produced sustained myofibroblast gene elevation and enhanced TGFβ 
responsiveness in these cells even after 5-Aza withdrawal (Figure 5-3B and Figure 5-3C), 
indicating that DNMT1 is crucial in maintaining endothelial characteristics that are transmissible 
in culture. These preliminary results together demonstrate that epigenetic status is important in 
the regulation of endothelial heterogeneity and plasticity. Mesenchymal genes in non-responder 
EC can be unsilenced via inhibiting DNMTs with 5-Aza or siRNA knockdown of DNMT1, 
suggesting that DNMT1 is crucial in regulating endothelial identity and TGFβ sensitivity.  
How DNMT1 suppresses myofibroblast genes in EC, however, remains unclear. 
Myofibroblast gene repression by DNMT1 can be achieved in two possible ways: 1) direct 
silencing of either myofibroblast genes or positive regulators of myofibroblast gene by promoter 
hypermethylation, and 2) through a methylation-independent silencing mechanism by interacting 
with a gene repressor complex. Both forms of DNMT-mediated myofibroblast gene regulation 
have been shown by previous studies of gene expression in myofibroblast differentiation and 
EMT. For example, in rat alveolar epithelial type II cells, hypermethylation of the CpG-rich 
regions in SMA promoter is responsible for inactivation of the SMA gene 7. DNMT expression 
and activity are higher in epithelial cells than in lung fibroblasts in which SMA can be induced by 
5-Aza inhibition of DNMTs 7. DNMTs can also complex with transcriptional repressors including 
SNAIL1 and histone deacetylases (HDACs) 1 and 2 to silence genes in a DNA methylation-
independent fashion 8,9. This methylation-independent activity of DNMTs was elegantly 
demonstrated using cells expressing a splice variant of DNMT1 that lacks its catalytic domain 10. 
Albeit exhibiting a steep reduction in its methylation activity, this truncated DNMT1 was able to 
bind to SNAIL1 to down-regulate epithelial genes during EMT, suggesting that DNMTs mediate 
gene silencing through multiple mechanisms.  
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As the effect of DNMT1 in our TGFβ non-responder EC is effectively inhibited by 5-Aza – 
a cytidine analogue that blocks the enzymatic activities of DNMT1, it is highly likely that direct 
hypermethylation of the mesenchymal genes by DNMT1 is responsible for the suppression of 
these genes in the non-responders. To test this hypothesis, future studies using qPCR-based 
locus or regional specific DNA methylation analysis can be carried out to compare methylation 
patterns of genes of interest in TGFβ responder EC and non-responder EC. We expect to 
observe higher promoter methylation in SMA and other myofibroblast genes in the non-
responders than in the responders. Alternatively, whole-genome bisulfite sequencing can be 
utilized to examine the global methylation status of these two cell types.  
Another observation from our preliminary data is that TGFβ alone suppresses DNMT1 
levels in EC (refer to Figure 5-2). Examination of the correlation of TGFβ and DNMT1 levels in 
different EC clones revealed an inverse relationship (Figure 5-4). Furthermore, long-term TGFβ 
stimulation represses Dnmt1 and turns on sustained SMA expression in TGFβ non-responder 
EC even in the absence of TGFβ (Figure 5-5), suggesting chronic TGFβ stimulation may induce 
epigenetic modifications to switch on persistent myofibroblast gene expression (Figure 5-4). 
Indeed, in agreement with our findings, others have shown that crosstalk between TGFβ and 
DNMTs modulates gene silencing and activation in different cell types. TGFβ can achieve locus-
specific promoter demethylation to activate genes via inhibition of specific DNMT isoforms 11,12. 
Suppression of DNMTs with 5-Aza, on the other hand, can enhance TGFβ signaling and 
downstream transcriptional activities in cell lines and primary cultures 14. However, in ovarian 
tumor cells, TGFβ may induce global DNA methylation alterations that favor EMT through 
increasing DNMT expression and activity, suggesting that the interaction between these two 
factors may be cell-dependent 13. 
As TGFβ levels are highly up-regulated in a chronic inflammatory environment such as 
tumors, it is possible that extended exposure of TGFβ can reshape the epigenetic landscape 
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and sensitize EC to undergo EndMT by down-regulating DNMT1 (Figure 5-6). DNMT1 likely 
plays a key role in maintaining endothelial identity, and loss of DNMT1 predisposes EC to 
TGFβ-stimulated EndMT, i.e., turning non-responder EC into responders. The relationship 
between TGFβ and DNMT1 can be examined in TGFβ non-responder EC using Lentiviral 
overexpression of Dnmt1, which we predict will increase the non-responders’ resistance to 
TGFβ insult. TGFβ signaling can be ablated by deletion of Tgfβr2 using the CRISPR-cas gene 
editing system in vitro or an endothelial-specific (Cdhcre/ER) mouse line, which would likely 
increase DNMT1 expression and decrease EndMT frequency. Regulatory pathways that 
facilitate TGFβ-mediated Dnmt1 suppression can be parsed out using small-molecule inhibitors 
that target TGFβ signaling factors. In addition, DNA methylation analysis on cells exposed to 
long-term TGFβ can be performed to interrogate the effect of TGFβ on myofibroblast gene 
methylation. Although both TGFβ and DNMT1 are functionally diverse and may mediate 
expression of other genes, studies to establish the interactions between these two factors in the 
context of EndMT will likely provide insight to the fundamental processes that control endothelial 
heterogeneity and myofibroblast activation.  
2. How does bFGF counteract TGFβ-stimulated EndMT?  
Our results in Chapter 4 have demonstrated the remarkable ability of bFGF to 
counteract EndMT stimulated by TGFβ. Ongoing investigation in our lab aims to understand the 
molecular mechanisms by which bFGF antagonizes TGFβ. We hypothesize that TGFβ-induced 
EndMT is blocked by one of the signaling cascades activated by bFGF/FGFR. Numerous 
signaling pathways, including Ras-Raf-MEK/ERK, PI3K/Akt, and phospholipase-C gamma 
(PLCγ), are mediated by bFGF signaling. Binding of bFGF to FGFR induces receptor 
dimerization and activation, which phosphorylates its major intracellular signaling components, 
FGFR substrate 2 (FRS2) and PLCγ 15. While FRS2 transduces signaling mainly through the 
Ras-Raf-MEK/ERK and PI3K/Akt/mTOR pathways, PLCγ triggers the release of intracellular 
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calcium, which activates downstream calcium-dependent enzymes to mediate a myriad of 
cellular responses. Additional pathways sequential to the FGF activation of Ras and Raf include 
p38 kinase and c-Jun N-terminal kinase (JNK), which form a branch parallel to MEK/ERK 
signaling 16. Although in occasional cellular contexts these pathways can induce differentiation 
and cell-cycle arrest, in most cases FGF ligands promote proliferation and migration 17.   
Recent work by Chen et al. suggests that bFGF is essential in preventing EndMT in the 
normal endothelium. bFGF signals through FGFR-FRS2 to up-regulate let-7, which in turn 
targets TGFβR1 to attenuate EndMT; blocked FGF signaling subsequent to chronic 
inflammation, on the contrary, leads to a reduction of let-7 and enhances TGFβ signaling which 
initiates EndMT 18. We carried out a Nanostring miRNA array to examine the miRNA profiles of 
NEC and TEC treated with bFGF or TGFβ. However, our results did not show significant 
variation in the levels of let-7 family members in either treatment group, suggesting that 
mechanisms other than miRNA regulation may be at play.  
In EC, activation of MEK/ERK signaling by bFGF is critical for cell proliferation, 
migration, survival, and VEGFR-dependent angiogenesis 19-21. MEK/ERK signaling is also 
implicated in the regulation of EMT 22. Remarkably, the bFGF analogue, aFGF, can reverse 
TGFβ-induced EMT through induction of MEK/ERK 23. aFGF strongly reduces SMAD2 
phosphorylation and suppresses mesenchymal genes SMA and MMPs. Epithelial gene 
expression is restored to normal levels by aFGF, an effect that is abolished specifically by a 
MEK inhibitor but not by inhibition of PI3K or p38. Corroborating this finding, Ichise and 
colleagues discovered that in lymphatic EC, bFGF opposed EndMT by diminishing TGFβ-
stimulated SMAD2 phosphorylation through MEK/ERK activation 24. Overexpression of the Ras 
protein, an upstream factor of MEK/ERK signaling, amplified bFGF-driven ERK signaling and 
prevented EndMT promoted by either bFGF withdrawal or TGFβ addition.  
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To test the role of MEK/ERK signaling in our cell system, we utilized two potent MEK 
inhibitors (U0126 and PD98059) to block bFGF signaling 25. Combination treatment of both 
inhibitors effectively abrogated the opposing effect of bFGF on TGFβ (Figure 5-7), whereas 
inhibition of other pathways downstream of bFGF, including p38, JNK, and PLCγ, had no effect 
(not shown). Unlike in lymphatic EC or EMT as previously reported, however, phosphorylation of 
SMAD2 or SMAD3 by TGFβ in the EC clones that we tested was unaffected by bFGF. These 
data suggest that the bFGF-MEK/ERK axis by may also counteract TGFβ-stimulated EndMT in 
a SMAD-independent manner. Our future goal is therefore to elucidate how MEK/ERK activation 
antagonizes TGFβ-regulated gene expression in TEC.  
It has been well documented that MEK/ERK signaling activated by other RTKs such as 
PDGFR mediates SMC differentiation 26,27. Activation of PDGFR by its ligand PDGF-BB potently 
induces MEK/ERK phosphorylation, which in turn phosphorylates an ETS-domain containing 
protein-1 (Elk-1), which is a member of the ETS transcription factors 28. Phosphorylated Elk-1 
binds to serum response factor (SRF) at the target gene promoter, hence disrupting the 
myocardin-SRF complex, which is the major transcription machinery driving the expression of 
SMC genes (also expressed in myofibroblasts) such as SM myosin heavy chain, calponin, SMA, 
and SM22 29. Elk-1 plays a dual role during this smooth muscle phenotypical switch, as it turns 
off the differentiation process by suppressing SMC genes but enhances the expression of 
growth-promoting genes such as c-Fos 28.  
In EndMT, the same set of myofibroblast/SMC genes is inhibited by bFGF, which is a 
known activator of Elk-1 30. It is therefore conceivable that bFGF may employ the same 
mechanism in EC to oppose TGFβ-regulated gene expression. A few experimental approaches 
can be used to test this proposition. First, siRNA or the CRISPR-cas system can be employed 
to deplete Elk-1 in EC clones and to determine if Elk-1 is essential in bFGF’s antagonistic 
action. Second, the interaction between SRF and Elk-1 can be examined using co-
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immunoprecipitation (Co-IP) assays, in which SRF is pulled down by an SRF antibody in cells 
treated with bFGF and TGFβ, and SRF binding with Elk-1 is then determined by detection of the 
phospho-Elk. Third, Elk-1 activation and activity can be further investigated with a luciferase 
reporter that contains the SRF binding consensus sequence CArG. If bFGF signaling inhibits 
TGFβ by disrupting SRF complex, we should observe a reduction in TGFβ-induced luciferase 
activity after addition of bFGF. Dissecting the mechanisms that control the negative regulatory 
effect of bFGF on TGFβ will shed light on how myofibroblasts are activated and reversed, and 
may help design targeted therapies for cancer and fibrotic diseases.  
3. What is the role of endothelial TGFβ signaling in tumor progression? 
TGFβ is a principal EndMT inducer in tumors and other diseases. It is also important in 
modulating endothelial functions, including angiogenesis and proliferation 31. In vivo studies 
show that constitutive deletion of TGFβ signaling components in EC impairs cardiovascular 
development and results in lethality that phenocopies the global TGFβ signaling deletion models 
32. Conditional ablation of endothelial-specific TGFβ activities during embryonic or perinatal 
stage leads to retinal and cerebral vascular defects and hemorrhage 33,34, pointing to an 
essential role of TGFβ in the development of vascular integrity. In tumors, loss of endoglin, 
which is a negative regulator of TGFβ signaling, results in increased EndMT and metastasis 35. 
However, studies on the direct impact of endothelial TGFβ signaling in tumor growth and 
metastasis are lacking.  
Our lab has generated a conditional EC Tgfβr2 knockout reporter mouse (Cdh5Cre(ERT2): 
ZsGreenl/s/l:Tgfβr2fl/fl) by crossing the inducible reporter mice Cdh5Cre(ERT2):ZsGreenl/s/l with mice 
carrying a floxed Tgfβr2  allele (Tgfβr2fl/fl). In this knockout mouse, exon 4 of the Tgfβr2 gene is 
targeted for deletion, rendering the receptor non-functional and thus abolishing all TGFβ-
regulated activities 36. Tumors can be introduced orthotopically into these mice to study the 
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effect of endothelial signaling in tumor progression. Careful quantification of tumor size, EndMT 
frequency, and tumor vascular morphology will establish the function of endothelial TGFβ 
signaling in primary tumors. More importantly, because of the crucial role of TGFβ in EndMT 
and vascular integrity maintenance, which may be key in regulating tumor metastasis, we will 
use a tail-vein tumor injection model in the conditional EC Tgfβr2 knockout mice to determine 
the effect of TGFβ signaling in metastatic seeding in the lungs.  
TGFβ often imparts dual effects on tumor growth and angiogenesis. For example, TGFβ 
can be tumor-limiting during early tumorigenesis but tumor-promoting in advanced tumors 37. 
Similarly, TGFβ can either enhance or inhibit angiogenesis, apoptosis, or proliferation of EC, 
depending on the strength and timing of the TGFβ signal 38. The in vivo tumor models where a 
large number of tumor cells are artificially implanted or injected may not reflect clinical cancer 
growth where a small number of mutated cells develop into a tumor mass over time. To solve 
this problem, an alternative approach can be utilized. We can backcross the Cdh5Cre(ERT2): 
ZsGreenl/s/l:Tgfβr2fl/fl mouse onto a GEMM tumor background (e.g., C3-TAg mammary tumor 
model) which closely resembles clinical tumor progression. Deletion of endothelial TGFβ 
signaling can be induced at different tumor stages to evaluate tumor progression.   
In conclusion, our work in this thesis has presented the novel finding of an autocrine 
interaction between TGFβ and bFGF, and our preliminary data suggest that DNMT1-regulated 
DNA methylation may be critical in maintaining endothelial identity in the face of TGFβ 
challenge. Future work will attempt to elucidate the relationship between TGFβ, DNMT1, and 
bFGF, which will help to clarify the underlying mechanisms that mediate EndMT and pinpoint 
the regulatory elements of these myofibroblast genes. In addition, understanding the impact of 
endothelial TGFβ signaling in tumors may delineate the roles of EC and tumor 
microenvironment in tumor progression, and hopefully facilitate the development of new 
therapeutics for cancer patients.    
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Figures 
   
Figure 5-1. Inhibition of DNMTs by 5-Aza activates myofibroblast genes. 
(A) Western analysis showing that SMA expression in TGFβ non-responders can be turned on 
by pre-incubating non-responder EC clones with 5-Aza. SMA expression was up-regulated in 
the presence of TGFβ2 and 5-Aza (48-hour treatment). (B) Expression of SMA in non-responder 
EC after TGFβ2 and 5-Aza treatment by immunofluoresence. (Green: CD31; red: SMA; blue: 
DAPI; scale bar: 10 µm) (C) qPCR analysis of gene expression in a TGFβ non-responder EC 
treated with TGFβ2 with or without 5-Aza pre-incubation. All cell cultures was pre-incubated with 
or without 5 µM of 5-Aza for 24 hours before treatment with 10 ng/mL TGFβ2 for additional 48 
hours. 
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Figure 5-2. Depletion of DNMT1 by siRNA up-regulates myofibroblast genes in TGFβ non-
responder EC clones.  
(A) Western analysis of DNMT1 and SMA expression in TGFβ non-responders. DNMT1 was 
knocked down by siRNA in these clones before treatment with TGFβ2 for 48 hours. (B) Relative 
mRNA expression of Dnmt isoforms and myofibroblast markers after TGFβ exposure in Dnmt1 
knocked down TGFβ non-responder EC.  
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Figure 5-3. Transient inhibition of DNMTs by 5-Aza induces sustained myofibroblast gene 
expression in TGFβ non-responders. 
(A) Phase contrast images of in TGFβ non-responder EC either maintained in EC growth media 
(left) or pre-exposed to pulse 5-Aza treatment for 24 hours and then returned to EC growth 
media (right).  (B) Western analysis of SMA expression in TGFβ non-responders pulse treated 
with or without 5-Aza for 24 hours. TGFβ2 was added to cells for 48 hours in the absence of 5-
Aza. (C) TGFβ-induced relative mRNA expression of myofibroblast markers in TGFβ non-
responders with or without transient pretreatment of 5-Aza.  
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Figure 5-4. DNMT1 and SMA levels are inversely correlated in TGFβ responder and non-
responder clones. 
(A) Western analysis of DNMT1 and SMA levels in different EC clones with or without TGFβ2 
stimulation. (B) TGFβ-induced relative mRNA expression of Dnmt1 and Acata2 in EC clones 
with or without TGFβ2 stimulation.  
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Figure 5-5. Long-term TGFβ stimulation suppresses DNMT1 and induces persistent SMA 
expression in non-responder EC. 
(A) Schematics of long-term TGFβ treatment of the non-responder EC. (B) Western analysis of 
DNMT1 and SMA expression in TGFβ non-responders challenged with 10 ng/mL TGFβ for 0 – 
10 days (left panels), or first challenged with TGFβ and then cultured in growth media without 
TGFβ for additional two days.  
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Figure 5-6. TGFβ stimulates myofibroblast conversion from EC at two levels: 
suppression of DNMT1 and direct up-regulation of myofibroblast genes. 
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Figure 5-7. Inhibition of both MEK and ERK pathways blocks the antagonistic effect of 
bFGF on TGFβ. 
Western analysis of SMA in TGFβ responders. TGFβ and bFGF were added to the cell media 
for 48 hours in the presence or absence of MEK inhibitors PD98059 (PD) and U0126.      
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